US8158424B2	NNP	O
-	:	O
Primate	NNP	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
medium	NN	O
containing	VBG	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
and	CC	O
lithium	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/209,325	CD	O
filed	VBD	O
Sep.	NNP	O
12	CD	O
,	,	O
2008	CD	O
,	,	O
now	RB	O
abandoned	VBN	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/221,457	CD	O
,	,	O
filed	VBD	O
Sep.	NNP	O
8	CD	O
,	,	O
2005	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,449,334	CD	O
issued	VBD	O
Nov.	NNP	O
11	CD	O
,	,	O
2008	CD	O
,	,	O
which	WDT	O
claimed	VBD	O
priority	NN	O
from	IN	O
U.S.	NNP	O
provisional	JJ	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
60/608,040	CD	O
filed	VBD	O
Sep.	NNP	O
8	CD	O
,	,	O
2004	CD	O
.	.	O
This	DT	O
application	NN	O
is	VBZ	O
also	RB	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/242,085	CD	O
filed	VBD	O
Sep.	NNP	O
30	CD	O
,	,	O
2008	CD	O
,	,	O
now	RB	O
abandoned	VBN	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/221,516	CD	O
filed	VBD	O
Sep.	NNP	O
8	CD	O
,	,	O
2005	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,442,548	CD	O
issued	VBN	O
Oct.	NNP	O
28	CD	O
,	,	O
2008	CD	O
,	,	O
which	WDT	O
claimed	VBD	O
priority	NN	O
from	IN	O
U.S.	NNP	O
provisional	JJ	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
Nos	NNP	O
.	.	O
60/695,100	CD	O
filed	VBD	O
Jun	NNP	O
.	.	O
29	CD	O
,	,	O
2005	CD	O
and	CC	O
60/608,040	CD	O
filed	VBD	O
Sep.	NNP	O
8	CD	O
,	,	O
2004	CD	O
.	.	O
Each	DT	O
of	IN	O
these	DT	O
applications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
STATEMENT	NNP	O
REGARDING	NNP	O
FEDERALLY	NNP	O
SPONSORED	NNP	O
RESEARCH	NNP	O
OR	NNP	O
DEVELOPMENT	NNP	O
Some	DT	O
of	IN	O
the	DT	O
work	NN	O
described	VBN	O
in	IN	O
this	DT	O
specification	NN	O
was	VBD	O
supported	VBN	O
by	IN	O
grants	NNS	O
from	IN	O
the	DT	O
U.S.	NNP	O
Government	NNP	O
and	CC	O
some	DT	O
was	VBD	O
not	RB	O
.	.	O
None	NN	O
of	IN	O
the	DT	O
work	NN	O
described	VBN	O
in	IN	O
this	DT	O
specification	NN	O
on	IN	O
the	DT	O
process	NN	O
of	IN	O
deriving	VBG	O
new	JJ	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
was	VBD	O
supported	VBN	O
by	IN	O
any	DT	O
grant	JJ	O
money	NN	O
from	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
government	NN	O
.	.	O
New	NNP	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cell	NN	O
derivations	NNS	O
and	CC	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
exclusively	RB	O
at	IN	O
WiCell	NNP	O
,	,	O
using	VBG	O
privately	RB	O
funded	VBN	O
WiCell	NNP	O
facilities	NNS	O
,	,	O
equipment	NN	O
and	CC	O
personnel	NNS	O
.	.	O
To	TO	O
the	DT	O
extent	NN	O
this	DT	O
invention	NN	O
was	VBD	O
made	VBN	O
with	IN	O
United	NNP	O
States	NNPS	O
government	NN	O
support	NN	O
,	,	O
the	DT	O
award	NN	O
was	VBD	O
provided	VBN	O
by	IN	O
:	:	O
NIH	NNP	O
R24-RR017721	NNP	O
and	CC	O
P20-GMO69981	NNP	O
.	.	O
The	DT	O
United	NNP	O
States	NNPS	O
government	NN	O
has	VBZ	O
certain	JJ	O
rights	NNS	O
in	IN	O
this	DT	O
invention	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Primate	NNP	O
embryonic	JJ	O
stem	NN	O
(	(	O
ES	NNP	O
)	)	O
cells	NNS	O
and	CC	O
the	DT	O
recently-described	JJ	O
induced	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
(	(	O
iPS	NN	O
)	)	O
(	(	O
collectively	RB	O
,	,	O
“	JJ	O
pluripotent	NN	O
cells	NNS	O
”	VBP	O
)	)	O
can	MD	O
proliferate	VB	O
without	IN	O
limit	NN	O
and	CC	O
can	MD	O
differentiate	VB	O
into	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
embryonic	JJ	O
germ	NN	O
layers	NNS	O
.	.	O
ES	NNP	O
cells	NNS	O
are	VBP	O
stem	JJ	O
cells	NNS	O
found	VBN	O
in	IN	O
or	CC	O
derived	VBN	O
from	IN	O
embryos	NN	O
.	.	O
ES	NNP	O
cells	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
differentiation	NN	O
into	IN	O
most	JJS	O
,	,	O
if	IN	O
not	RB	O
all	DT	O
,	,	O
of	IN	O
the	DT	O
differentiated	VBN	O
cell	NN	O
types	NNS	O
of	IN	O
a	DT	O
mature	NN	O
body	NN	O
.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
iPS	JJ	O
cells	NNS	O
behave	VBP	O
in	IN	O
culture	NN	O
essentially	RB	O
the	DT	O
same	JJ	O
as	IN	O
ES	NNP	O
cells	NNS	O
.	.	O
iPS	NN	O
cells	NNS	O
and	CC	O
ES	NNP	O
cells	NNS	O
express	VBP	O
one	CD	O
or	CC	O
more	JJR	O
pluripotent	JJ	O
cell-specific	JJ	O
marker	NN	O
,	,	O
such	JJ	O
as	IN	O
Oct-4	NNP	O
,	,	O
SSEA-3	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
Tra	NNP	O
1-81	CD	O
,	,	O
and	CC	O
Nanog	NNP	O
(	(	O
Yu	NNP	B
et	RB	I
al	RB	I
.	.	I
Science	NN	I
,	,	I
Vol	NNP	I
.	.	I
318.	CD	I
no	DT	I
.	.	I
5858	CD	I
,	,	I
pp	NN	I
.	.	I
1917-1920	CD	I
(	(	I
2007	CD	I
)	)	I
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
)	)	O
Also	RB	O
,	,	O
recent	JJ	O
findings	NNS	O
of	IN	O
Chan	NNP	O
,	,	O
suggest	VBP	O
that	IN	O
expression	NN	O
of	IN	O
Tra	NNP	O
1-60	JJ	O
,	,	O
DNMT3B	NNP	O
,	,	O
and	CC	O
REX1	NNP	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
positively	RB	O
identify	VB	O
fully	RB	O
reprogrammed	VBN	O
iPS	JJ	O
cells	NNS	O
,	,	O
whereas	NNS	O
alkaline	VBP	O
phosphatase	NN	O
,	,	O
SSEA-4	NNP	O
,	,	O
GDF3	NNP	O
,	,	O
hTERT	NN	O
,	,	O
and	CC	O
NANOG	NNP	O
are	VBP	O
insufficient	JJ	O
as	IN	O
markers	NNS	O
of	IN	O
fully	RB	O
reprogrammed	VBN	O
iPS	JJ	O
cells	NNS	O
.	.	O
(	(	O
Chan	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nat	NNP	I
.	.	I
Biotech	NNP	I
.	.	I
27:1033-1037	CD	I
(	(	I
2009	CD	I
)	)	I
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
)	)	O
.	.	O
Subsequent	JJ	O
references	NNS	O
herein	VBP	O
to	TO	O
primate	VB	O
or	CC	O
human	JJ	O
ES	NNP	O
cells	NNS	O
and	CC	O
the	DT	O
like	JJ	O
are	VBP	O
intended	VBN	O
to	TO	O
apply	VB	O
with	IN	O
equal	JJ	O
force	NN	O
to	TO	O
iPS	VB	O
cells	NNS	O
.	.	O
Pluripotent	NN	O
cells	NNS	O
are	VBP	O
of	IN	O
high	JJ	O
interest	NN	O
to	TO	O
the	DT	O
research	NN	O
community	NN	O
and	CC	O
regenerative	JJ	O
industry	NN	O
because	IN	O
they	PRP	O
are	VBP	O
capable	JJ	O
of	IN	O
indefinite	JJ	O
proliferation	NN	O
in	IN	O
culture	NN	O
.	.	O
Thus	RB	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
principle	NN	O
,	,	O
pluripotent	NN	O
cells	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
supplying	VBG	O
cells	NNS	O
and	CC	O
tissues	NNS	O
for	IN	O
replacement	NN	O
of	IN	O
failing	VBG	O
or	CC	O
defective	JJ	O
human	JJ	O
tissue	NN	O
.	.	O
This	DT	O
is	VBZ	O
why	WRB	O
the	DT	O
existence	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
offers	VBZ	O
the	DT	O
potential	NN	O
of	IN	O
unlimited	JJ	O
amounts	NNS	O
of	IN	O
human	JJ	O
cells	NNS	O
and	CC	O
tissues	NNS	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
therapeutic	JJ	O
protocols	NNS	O
to	TO	O
assist	VB	O
in	IN	O
human	JJ	O
health	NN	O
.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
in	IN	O
the	DT	O
future	NN	O
that	WDT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
will	MD	O
be	VB	O
proliferated	VBN	O
and	CC	O
directed	VBN	O
to	TO	O
differentiate	VB	O
into	IN	O
specific	JJ	O
lineages	NNS	O
so	RB	O
as	IN	O
to	TO	O
develop	VB	O
differentiated	JJ	O
cells	NNS	O
or	CC	O
tissues	NNS	O
which	WDT	O
can	MD	O
be	VB	O
transplanted	VBN	O
into	IN	O
human	JJ	O
bodies	NNS	O
for	IN	O
therapeutic	JJ	O
purposes	NNS	O
.	.	O
Human	NNP	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
and	CC	O
the	DT	O
differentiated	JJ	O
cells	NNS	O
that	WDT	O
may	MD	O
be	VB	O
derived	VBN	O
from	IN	O
them	PRP	O
are	VBP	O
also	RB	O
powerful	JJ	O
scientific	JJ	O
tools	NNS	O
for	IN	O
the	DT	O
study	NN	O
of	IN	O
human	JJ	O
cellular	JJ	O
and	CC	O
developmental	JJ	O
systems	NNS	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
basic	JJ	O
techniques	NNS	O
to	TO	O
create	VB	O
and	CC	O
culture	NN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
.	.	O
The	DT	O
previously	RB	O
reported	VBN	O
techniques	NNS	O
do	VBP	O
work	NN	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
limitations	NNS	O
and	CC	O
drawbacks	NNS	O
to	TO	O
many	JJ	O
of	IN	O
the	DT	O
procedures	NNS	O
currently	RB	O
used	VBN	O
to	TO	O
culture	NN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
.	.	O
One	CD	O
limitation	NN	O
of	IN	O
particular	JJ	O
concern	NN	O
is	VBZ	O
that	IN	O
most	JJS	O
existing	VBG	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
have	VBP	O
been	VBN	O
,	,	O
to	TO	O
one	CD	O
degree	NN	O
or	CC	O
another	DT	O
,	,	O
exposed	VBN	O
directly	RB	O
to	TO	O
mouse	VB	O
cells	NNS	O
or	CC	O
to	TO	O
a	DT	O
medium	NN	O
in	IN	O
which	WDT	O
mouse	NN	O
cells	NNS	O
have	VBP	O
been	VBN	O
previously	RB	O
cultured	VBN	O
.	.	O
This	DT	O
is	VBZ	O
because	IN	O
the	DT	O
original	JJ	O
techniques	NNS	O
for	IN	O
generating	VBG	O
and	CC	O
culturing	VBG	O
human	JJ	O
ES	NNP	O
cells	NNS	O
required	VBD	O
using	VBG	O
mouse	NN	O
embryonic	JJ	O
fibroblast	NN	O
(	(	O
MEF	NNP	O
)	)	O
feeder	NN	O
cells	NNS	O
as	IN	O
a	DT	O
feeder	NN	O
layer	NN	O
on	IN	O
which	WDT	O
human	JJ	O
ES	NNP	O
cells	NNS	O
could	MD	O
be	VB	O
cultured	VBN	O
.	.	O
The	DT	O
fibroblast	NN	O
feeder	NN	O
cells	NNS	O
act	NN	O
,	,	O
through	IN	O
some	DT	O
as	IN	O
yet	RB	O
incompletely	RB	O
understood	JJ	O
mechanism	NN	O
,	,	O
to	TO	O
encourage	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
to	TO	O
remain	VB	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
A	DT	O
by-product	NN	O
of	IN	O
such	JJ	O
techniques	NNS	O
is	VBZ	O
that	IN	O
some	DT	O
human	JJ	O
ES	NNP	O
cells	NNS	O
from	IN	O
existing	VBG	O
cell	NN	O
lines	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
exhibit	VB	O
the	DT	O
sialic	JJ	O
residue	JJ	O
Neu5Gc	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
not	RB	O
normally	RB	O
made	VBN	O
by	IN	O
human	JJ	O
cells	NNS	O
but	CC	O
is	VBZ	O
made	VBN	O
by	IN	O
murine	NN	O
cells	NNS	O
,	,	O
and	CC	O
has	VBZ	O
received	VBN	O
much	JJ	O
attention	NN	O
in	IN	O
the	DT	O
press	NN	O
.	.	O
Later	RB	O
,	,	O
it	PRP	O
was	VBD	O
discovered	VBN	O
that	IN	O
the	DT	O
benefits	NNS	O
MEF	NNP	O
feeder	NN	O
cells	NNS	O
provide	VBP	O
to	TO	O
stem	VB	O
cells	NNS	O
grown	VBN	O
in	IN	O
culture	NN	O
could	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
exposing	VBG	O
stem	NN	O
cells	NNS	O
to	TO	O
“	VB	O
conditioned	VBN	O
medium.	JJ	O
”	NN	O
Conditioned	NNP	O
medium	NN	O
is	VBZ	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
medium	NN	O
in	IN	O
which	WDT	O
feeder	NN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
MEFs	NNP	O
,	,	O
had	VBD	O
been	VBN	O
previously	RB	O
cultured	VBN	O
.	.	O
In	IN	O
conditioned	JJ	O
medium	NN	O
,	,	O
either	CC	O
the	DT	O
feeder	NN	O
cells	NNS	O
impart	VBP	O
some	DT	O
factor	NN	O
to	TO	O
the	DT	O
medium	NN	O
or	CC	O
remove	VB	O
some	DT	O
factor	NN	O
from	IN	O
the	DT	O
medium	NN	O
,	,	O
which	WDT	O
allows	VBZ	O
stem	NN	O
cells	NNS	O
to	TO	O
be	VB	O
cultured	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
Although	IN	O
the	DT	O
mechanisms	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
conditioned	JJ	O
medium	NN	O
have	VBP	O
not	RB	O
been	VBN	O
fully	RB	O
elucidated	VBN	O
,	,	O
the	DT	O
result	NN	O
is	VBZ	O
that	IN	O
conditioned	JJ	O
medium	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
with	IN	O
minimal	JJ	O
differentiation	NN	O
.	.	O
Both	DT	O
direct	JJ	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
murine	NN	O
feeder	NN	O
cells	NNS	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
conditioned	JJ	O
media	NNS	O
raise	VBP	O
the	DT	O
concern	NN	O
that	WDT	O
one	CD	O
or	CC	O
more	JJR	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
virus	NN	O
,	,	O
could	MD	O
be	VB	O
transmitted	VBN	O
from	IN	O
the	DT	O
mouse	NN	O
cells	NNS	O
to	TO	O
the	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
If	IN	O
one	CD	O
of	IN	O
the	DT	O
applied	JJ	O
objectives	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
is	VBZ	O
to	TO	O
create	VB	O
cells	NNS	O
and	CC	O
tissues	NNS	O
which	WDT	O
can	MD	O
ultimately	RB	O
be	VB	O
transplanted	VBN	O
into	IN	O
a	DT	O
human	JJ	O
body	NN	O
,	,	O
it	PRP	O
is	VBZ	O
highly	RB	O
desirable	JJ	O
to	TO	O
generate	VB	O
stem	NN	O
cells	NNS	O
that	WDT	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
cells	NNS	O
of	IN	O
another	DT	O
species	NNS	O
or	CC	O
to	TO	O
media	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
culture	NN	O
cells	NNS	O
of	IN	O
another	DT	O
species	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
defining	VBG	O
a	DT	O
culture	NN	O
condition	NN	O
,	,	O
which	WDT	O
will	MD	O
permit	VB	O
the	DT	O
proliferation	NN	O
and	CC	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
a	DT	O
fibroblast	NN	O
feeder	NN	O
layer	NN	O
,	,	O
is	VBZ	O
of	IN	O
great	JJ	O
interest	NN	O
in	IN	O
the	DT	O
continued	JJ	O
development	NN	O
of	IN	O
techniques	NNS	O
for	IN	O
the	DT	O
long	JJ	O
term	NN	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
Several	JJ	O
medium	NN	O
formulations	NNS	O
will	MD	O
permit	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
to	TO	O
remain	VB	O
undifferentiated	JJ	O
for	IN	O
some	DT	O
time	NN	O
,	,	O
but	CC	O
the	DT	O
undifferentiated	JJ	O
state	NN	O
often	RB	O
fails	VBZ	O
to	TO	O
maintain	VB	O
itself	PRP	O
.	.	O
The	DT	O
inventors	NNS	O
here	RB	O
have	VBP	O
found	VBN	O
several	JJ	O
medium	NN	O
formulations	NNS	O
that	WDT	O
permit	VBP	O
the	DT	O
cultivation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
for	IN	O
one	CD	O
or	CC	O
two	CD	O
passages	NNS	O
without	IN	O
severe	JJ	O
differentiation	NN	O
,	,	O
but	CC	O
then	RB	O
the	DT	O
cells	NNS	O
differentiate	VBP	O
rapidly	RB	O
upon	IN	O
subsequent	JJ	O
passages	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
“	JJ	O
passage	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
herein	RB	O
as	IN	O
the	DT	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
from	IN	O
an	DT	O
initial	JJ	O
seed	NN	O
culture	NN	O
in	IN	O
a	DT	O
culture	NN	O
vessel	NN	O
to	TO	O
confluence	VB	O
in	IN	O
the	DT	O
same	JJ	O
culture	NN	O
vessel	NN	O
.	.	O
The	DT	O
inventors	NNS	O
have	VBP	O
come	VBN	O
to	TO	O
believe	VB	O
that	IN	O
in	IN	O
order	NN	O
for	IN	O
a	DT	O
culture	NN	O
medium	NN	O
to	TO	O
truly	VB	O
support	VB	O
the	DT	O
indefinite	JJ	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
differentiation	NN	O
and	CC	O
without	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
medium	NN	O
that	WDT	O
is	VBZ	O
conditioned	VBN	O
therewith	NN	O
,	,	O
the	DT	O
medium	NN	O
must	MD	O
be	VB	O
capable	JJ	O
of	IN	O
supporting	VBG	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
a	DT	O
substantially	RB	O
uniform	JJ	O
and	CC	O
undifferentiated	JJ	O
state	NN	O
for	IN	O
at	IN	O
least	JJS	O
five	CD	O
passages	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
important	JJ	O
that	IN	O
the	DT	O
cultures	NNS	O
remain	VBP	O
relatively	RB	O
homogenous	JJ	O
and	CC	O
undifferentiated	JJ	O
throughout	IN	O
the	DT	O
culture	NN	O
period	NN	O
and	CC	O
retain	VB	O
all	DT	O
of	IN	O
the	DT	O
important	JJ	O
characteristics	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
A	DT	O
characteristic	JJ	O
trait	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
is	VBZ	O
that	IN	O
,	,	O
if	IN	O
conditions	NNS	O
are	VBP	O
less	JJR	O
than	IN	O
ideal	NN	O
,	,	O
the	DT	O
cells	NNS	O
have	VBP	O
a	DT	O
tendency	NN	O
to	TO	O
differentiate	VB	O
.	.	O
It	PRP	O
is	VBZ	O
easy	JJ	O
to	TO	O
induce	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
to	TO	O
differentiate	VB	O
,	,	O
while	IN	O
it	PRP	O
is	VBZ	O
challenging	VBG	O
to	TO	O
maintain	VB	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
in	IN	O
culture	NN	O
.	.	O
Most	JJS	O
culture	NN	O
conditions	NNS	O
will	MD	O
result	VB	O
in	IN	O
some	DT	O
level	NN	O
of	IN	O
unwanted	JJ	O
differentiation	NN	O
,	,	O
particularly	RB	O
around	IN	O
the	DT	O
periphery	NN	O
of	IN	O
the	DT	O
growing	VBG	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
colony	NN	O
.	.	O
While	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
with	IN	O
some	DT	O
degree	NN	O
of	IN	O
unwanted	JJ	O
differentiation	NN	O
,	,	O
the	DT	O
objective	NN	O
is	VBZ	O
to	TO	O
define	VB	O
a	DT	O
culture	NN	O
condition	NN	O
that	WDT	O
permits	VBZ	O
the	DT	O
culture	NN	O
to	TO	O
remain	VB	O
as	RB	O
undifferentiated	JJ	O
as	IN	O
possible	JJ	O
,	,	O
i.e.	JJ	O
,	,	O
with	IN	O
as	IN	O
few	JJ	O
differentiated	JJ	O
cells	NNS	O
as	IN	O
possible	JJ	O
.	.	O
To	TO	O
achieve	VB	O
this	DT	O
objective	NN	O
,	,	O
the	DT	O
inventors	NNS	O
have	VBP	O
used	VBN	O
particularly	RB	O
stringent	JJ	O
standards	NNS	O
to	TO	O
define	VB	O
conditions	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
indefinite	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
,	,	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
The	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
morphological	JJ	O
characteristics	NNS	O
.	.	O
Undifferentiated	JJ	O
stem	NN	O
cells	NNS	O
have	VBP	O
a	DT	O
characteristic	JJ	O
morphology	NN	O
,	,	O
i.e.	FW	O
,	,	O
small	JJ	O
and	CC	O
compact	JJ	O
cells	NNS	O
with	IN	O
clearly	RB	O
defined	VBN	O
cell	NN	O
borders	NNS	O
,	,	O
a	DT	O
morphology	NN	O
which	WDT	O
can	MD	O
be	VB	O
easily	RB	O
seen	VBN	O
by	IN	O
examination	NN	O
of	IN	O
a	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
under	IN	O
a	DT	O
microscope	NN	O
.	.	O
By	IN	O
contrast	NN	O
,	,	O
cells	NNS	O
which	WDT	O
have	VBP	O
differentiated	VBN	O
appear	JJ	O
larger	JJR	O
and	CC	O
more	RBR	O
diffuse	NN	O
with	IN	O
indistinct	JJ	O
cell	NN	O
borders	NNS	O
.	.	O
While	IN	O
some	DT	O
differentiated	JJ	O
cells	NNS	O
can	MD	O
,	,	O
and	CC	O
normally	RB	O
do	VBP	O
,	,	O
appear	VB	O
at	IN	O
the	DT	O
margin	NN	O
of	IN	O
colonies	NNS	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
,	,	O
the	DT	O
optimal	JJ	O
stem	NN	O
cell	NN	O
culture	NN	O
is	VBZ	O
one	CD	O
that	WDT	O
proliferates	VBZ	O
in	IN	O
the	DT	O
culture	NN	O
vessel	NN	O
with	IN	O
only	JJ	O
minimal	JJ	O
numbers	NNS	O
of	IN	O
cells	NNS	O
at	IN	O
the	DT	O
periphery	NN	O
of	IN	O
the	DT	O
culture	NN	O
appearing	VBG	O
to	TO	O
be	VB	O
differentiated	VBN	O
.	.	O
With	IN	O
experience	NN	O
,	,	O
stem	NN	O
cell	NN	O
researchers	NNS	O
can	MD	O
judge	VB	O
the	DT	O
status	NN	O
of	IN	O
differentiation	NN	O
and	CC	O
health	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
visually	RB	O
with	IN	O
good	JJ	O
accuracy	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
morphological	JJ	O
characteristics	NNS	O
,	,	O
biochemical	JJ	O
cell	NN	O
markers	NNS	O
are	VBP	O
routinely	RB	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
status	NN	O
of	IN	O
ES	NNP	O
cells	NNS	O
as	IN	O
undifferentiated	JJ	O
.	.	O
For	IN	O
example	NN	O
,	,	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
is	VBZ	O
regarded	VBN	O
as	IN	O
the	DT	O
most	RBS	O
reliable	JJ	O
marker	NN	O
of	IN	O
undifferentiated	JJ	O
status	NN	O
for	IN	O
ES	NNP	O
cells	NNS	O
.	.	O
Oct-4	NNP	O
is	VBZ	O
also	RB	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
markers	NNS	O
lost	VBN	O
as	IN	O
undifferentiated	JJ	O
cells	NNS	O
begin	VBP	O
to	TO	O
differentiate	VB	O
.	.	O
Other	JJ	O
biochemical	JJ	O
markers	NNS	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
status	NN	O
of	IN	O
undifferentiated	JJ	O
primate	NN	O
ES	NNP	O
cells	NNS	O
and	CC	O
human	JJ	O
ES	NNP	O
cells	NNS	O
include	VBP	O
:	:	O
SSEA-3	JJ	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
and	CC	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
but	CC	O
not	RB	O
SSEA-1	NNP	O
.	.	O
In	IN	O
contrast	NN	O
,	,	O
undifferentiated	JJ	O
mouse	NN	O
ES	NNP	O
cells	NNS	O
express	JJ	O
SSEA-1	NNP	O
,	,	O
but	CC	O
not	RB	O
SSEA-3	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
and	CC	O
Tra	NNP	O
1-81	CD	O
.	.	O
Tra	NNP	O
1-60	CD	O
,	,	O
and	CC	O
Tra	NNP	O
1-81	NNS	O
are	VBP	O
antibodies	NNS	O
to	TO	O
extracellular	VB	O
matrix	NN	O
molecules	NNS	O
synthesized	VBN	O
by	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
which	WDT	O
are	VBP	O
also	RB	O
markers	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
.	.	O
Further	RB	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
Nanog	NNP	O
is	VBZ	O
a	DT	O
transcription	NN	O
factor	NN	O
that	WDT	O
is	VBZ	O
essential	JJ	O
for	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
pluripotency	NN	O
and	CC	O
self	NN	O
renewal	NN	O
in	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
stringent	JJ	O
standards	NNS	O
required	VBN	O
for	IN	O
conditions	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
indefinite	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
,	,	O
the	DT	O
conditions	NNS	O
needed	VBN	O
for	IN	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
is	VBZ	O
an	DT	O
even	RB	O
more	RBR	O
stringent	JJ	O
.	.	O
This	DT	O
is	VBZ	O
because	IN	O
some	DT	O
culture	NN	O
conditions	NNS	O
which	WDT	O
support	VBP	O
the	DT	O
expansion	NN	O
and	CC	O
growth	NN	O
of	IN	O
existing	VBG	O
stem	NN	O
cells	NNS	O
lines	NNS	O
have	VBP	O
not	RB	O
proven	VBN	O
sufficient	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
.	.	O
It	PRP	O
appears	VBZ	O
that	IN	O
the	DT	O
capacity	NN	O
to	TO	O
support	VB	O
the	DT	O
initiation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
stem	NN	O
cells	NNS	O
is	VBZ	O
a	DT	O
capacity	NN	O
that	IN	O
not	RB	O
all	DT	O
stem	NN	O
cell	JJ	O
culture	NN	O
conditions	NNS	O
feature	NN	O
.	.	O
Accordingly	RB	O
,	,	O
media	NNS	O
to	TO	O
support	VB	O
initiation	NN	O
,	,	O
proliferation	NN	O
and	CC	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
primate	NN	O
stem	NN	O
cells	NNS	O
are	VBP	O
desired	VBN	O
by	IN	O
the	DT	O
stem	NN	O
cell	NN	O
industry	NN	O
.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
In	IN	O
a	DT	O
first	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
summarized	VBN	O
as	IN	O
a	DT	O
defined	JJ	O
medium	NN	O
for	IN	O
culturing	VBG	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
including	VBG	O
ES	NNP	O
cells	NNS	O
and	CC	O
iPS	JJ	O
cells	NNS	O
.	.	O
The	DT	O
medium	NN	O
is	VBZ	O
a	DT	O
serum-free	JJ	O
,	,	O
animal	JJ	O
product-free	JJ	O
medium	NN	O
that	WDT	O
supports	VBZ	O
the	DT	O
derivation	NN	O
and	CC	O
long-term	JJ	O
feeder-independent	JJ	O
culture	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
The	DT	O
defined	JJ	O
medium	NN	O
includes	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
(	(	O
FGF	NNP	O
)	)	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
gamma	NN	O
amino	NN	O
butyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
,	,	O
pipecolic	JJ	O
acid	NN	O
(	(	O
PA	NNP	O
)	)	O
,	,	O
and	CC	O
lithium	NN	O
(	(	O
Li	NNP	O
)	)	O
,	,	O
all	DT	O
in	IN	O
sufficient	JJ	O
amount	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
Optionally	RB	O
,	,	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
(	(	O
TGFβ	NNP	O
)	)	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
defined	JJ	O
medium	NN	O
in	IN	O
sufficient	JJ	O
amount	NN	O
so	RB	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
indefinitely	RB	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
,	,	O
pluripotent	JJ	O
and	CC	O
proliferative	JJ	O
state	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
culturing	VBG	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
with	IN	O
a	DT	O
defined	JJ	O
medium	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
the	DT	O
step	NN	O
of	IN	O
culturing	VBG	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
all	DT	O
in	IN	O
sufficient	JJ	O
amount	NN	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
an	DT	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
high	JJ	O
levels	NNS	O
of	IN	O
a	DT	O
FGF	NNP	O
,	,	O
lipids	NNS	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
so	IN	O
that	IN	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
indefinitely	RB	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
the	DT	O
creation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
new	JJ	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
cultured	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
and	CC	O
which	WDT	O
have	VBP	O
not	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
animal	JJ	O
products	NNS	O
,	,	O
feeder	NN	O
cells	NNS	O
,	,	O
or	CC	O
conditioned	VBD	O
medium	NN	O
.	.	O
Also	RB	O
disclosed	VBN	O
are	VBP	O
defined	VBN	O
long	JJ	O
term	NN	O
culture	NN	O
conditions	NNS	O
for	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
that	WDT	O
avoid	VBP	O
exposure	NN	O
to	TO	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
animal	JJ	O
cells	NNS	O
or	CC	O
proteins	NNS	O
in	IN	O
which	WDT	O
stem	NN	O
cells	NNS	O
are	VBP	O
often	RB	O
cultured	VBN	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
culturing	VBG	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media	NNS	O
,	,	O
the	DT	O
medium	NN	O
including	VBG	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
and	CC	O
Li	NNP	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
matrix	NN	O
is	VBZ	O
a	DT	O
solubilized	JJ	O
basement	NN	O
membrane	NN	O
preparation	NN	O
extracted	VBD	O
from	IN	O
the	DT	O
Engelbreth-Holm-Swarm	NNP	O
mouse	NN	O
sarcoma	NN	O
(	(	O
Matrigel™	NNP	O
)	)	O
or	CC	O
a	DT	O
matrix	NN	O
that	WDT	O
includes	VBZ	O
human	JJ	O
matrix	NN	O
proteins	NNS	O
collagen	VBP	O
IV	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
fibronectin	NN	O
,	,	O
laminin	NN	O
and	CC	O
vitronectin	NN	O
.	.	O
Preferably	RB	O
,	,	O
collagen	NN	O
IV	NNP	O
,	,	O
fibronectin	NN	O
,	,	O
laminin	NN	O
and	CC	O
vitronectin	NN	O
are	VBP	O
all	DT	O
included	VBN	O
in	IN	O
the	DT	O
matrix	NN	O
.	.	O
Optionally	RB	O
,	,	O
TGFβ	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
defined	JJ	O
medium	NN	O
.	.	O
The	DT	O
defined	JJ	O
growth	NN	O
factors	NNS	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
and	CC	O
Li	NNP	O
,	,	O
are	VBP	O
added	VBN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
wherein	NN	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
an	DT	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
having	VBG	O
in	IN	O
a	DT	O
culture	NN	O
vessel	NN	O
:	:	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
;	:	O
a	DT	O
matrix	NN	O
,	,	O
on	IN	O
which	WDT	O
the	DT	O
stem	NN	O
cells	NNS	O
can	MD	O
grow	VB	O
;	:	O
and	CC	O
a	DT	O
culture	NN	O
medium	NN	O
,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
comprises	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect	NN	O
,	,	O
the	DT	O
matrix	NN	O
includes	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
collagen	NN	O
IV	NNP	O
,	,	O
fibronectin	NN	O
,	,	O
laminin	NN	O
,	,	O
and	CC	O
vitronectin	NN	O
.	.	O
Preferably	RB	O
,	,	O
at	IN	O
least	JJS	O
two	CD	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
three	CD	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
all	DT	O
four	CD	O
human	JJ	O
matrix	NN	O
proteins	NNS	O
are	VBP	O
present	JJ	O
.	.	O
The	DT	O
culture	NN	O
medium	NN	O
includes	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
Li	NNP	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
so	IN	O
that	DT	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
medium	NN	O
also	RB	O
is	VBZ	O
free	JJ	O
of	IN	O
products	NNS	O
from	IN	O
non-human	JJ	O
animals	NNS	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
medium	NN	O
comprising	NN	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
and	CC	O
optionally	RB	O
TGFβ	NNP	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
wherein	NN	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
Suitably	RB	O
,	,	O
the	DT	O
FGF	NNP	O
concentration	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
between	IN	O
40	CD	O
ng/ml	NNS	O
and	CC	O
100	CD	O
ng/ml	NN	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect	NN	O
,	,	O
when	WRB	O
beta-mercaptoethanol	NN	O
was	VBD	O
either	RB	O
omitted	VBN	O
or	CC	O
added	VBN	O
at	IN	O
a	DT	O
concentration	NN	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
in	IN	O
the	DT	O
culture	NN	O
medium	NN	O
,	,	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
compared	VBN	O
to	TO	O
pluripotent	VB	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium	NN	O
,	,	O
having	VBG	O
a	DT	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
concentration	NN	O
of	IN	O
beta-mercaptoethanol	NN	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
initiating	VBG	O
a	DT	O
cultured	JJ	O
line	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
,	,	O
the	DT	O
method	NN	O
including	VBG	O
the	DT	O
step	NN	O
of	IN	O
plating	VBG	O
cells	NNS	O
from	IN	O
a	DT	O
blastocyst	NN	O
onto	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
originate	VB	O
and	CC	O
maintain	VB	O
a	DT	O
new	JJ	O
proliferating	VBG	O
stem	NN	O
cell	NN	O
line	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
Another	DT	O
aspect	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
culturing	VBG	O
new	JJ	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
including	VBG	O
the	DT	O
steps	NNS	O
of	IN	O
culturing	VBG	O
stem	NN	O
cells	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
isolated	VBN	O
from	IN	O
the	DT	O
inner	NN	O
cell	NN	O
mass	NN	O
of	IN	O
an	DT	O
embryo	NN	O
in	IN	O
the	DT	O
blastocyst	NN	O
stage	NN	O
in	IN	O
a	DT	O
medium	NN	O
including	VBG	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
the	DT	O
culturing	VBG	O
step	NN	O
being	VBG	O
conducted	VBN	O
on	IN	O
a	DT	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
comprising	VBG	O
collagen	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
protein	NN	O
selected	VBN	O
from	IN	O
fibronectin	NN	O
,	,	O
vitronectin	NN	O
,	,	O
and	CC	O
laminin	NN	O
,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
;	:	O
and	CC	O
serially	RB	O
expanding	VBG	O
the	DT	O
cells	NNS	O
which	WDT	O
proliferate	VBP	O
on	IN	O
the	DT	O
medium	NN	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
having	VBG	O
(	(	O
i	NN	O
)	)	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
that	WDT	O
comprises	VBZ	O
a	DT	O
humanized	JJ	O
matrix	NN	O
made	VBN	O
from	IN	O
human	JJ	O
collagen	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
human	JJ	O
protein	NN	O
selected	VBN	O
from	IN	O
fibronectin	NN	O
,	,	O
vitronectin	NN	O
and	CC	O
laminin	NN	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
a	DT	O
cell	NN	O
culture	NN	O
medium	NN	O
that	WDT	O
comprises	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
FGF	NNP	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
,	,	O
the	DT	O
medium	NN	O
being	VBG	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect	NN	O
,	,	O
the	DT	O
matrix	NN	O
includes	VBZ	O
collagen	NN	O
,	,	O
fibronectin	NN	O
,	,	O
vitronectin	NN	O
and	CC	O
laminin	NN	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
.	.	O
In	IN	O
this	DT	O
aspect	NN	O
,	,	O
the	DT	O
cultured	JJ	O
pluripotent	NN	O
cells	NNS	O
are	VBP	O
human	JJ	O
embryonic	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
which	WDT	O
do	VBP	O
not	RB	O
exhibit	VB	O
the	DT	O
sialic	JJ	O
acid	NN	O
Neu5Gc	NNP	O
and	CC	O
the	DT	O
medium	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
maintaining	VBG	O
the	DT	O
cells	NNS	O
through	IN	O
over	IN	O
twenty	JJ	O
passages	NNS	O
in	IN	O
culture	NN	O
while	IN	O
the	DT	O
cells	NNS	O
remain	VBP	O
undifferentiated	JJ	O
,	,	O
maintain	JJ	O
pluripotency	NN	O
,	,	O
and	CC	O
maintain	VBP	O
stable	JJ	O
karyotype	NN	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
cell	NN	O
culture	NN	O
medium	NN	O
having	VBG	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
a	DT	O
FGF	NNP	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
two	CD	O
members	NNS	O
selected	VBN	O
from	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
Li	NNP	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
feeder	NN	O
cells	NNS	O
and	CC	O
never	RB	O
having	VBG	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
that	IN	O
with	IN	O
the	DT	O
medium	NN	O
and	CC	O
culture	NN	O
system	NN	O
described	VBD	O
here	RB	O
,	,	O
one	CD	O
can	MD	O
establish	VB	O
and	CC	O
maintain	VB	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
undifferentiated	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
Another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
method	NN	O
of	IN	O
increasing	VBG	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
by	IN	O
culturing	VBG	O
the	DT	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media	NNS	O
,	,	O
the	DT	O
medium	NN	O
comprising	NN	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
,	,	O
and	CC	O
lithium	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
and	CC	O
such	JJ	O
that	IN	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
pluripotent	NN	O
cells	NNS	O
is	VBZ	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
compared	VBN	O
to	TO	O
pluripotent	VB	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium	NN	O
,	,	O
except	IN	O
wherein	PDT	O
the	DT	O
beta-mercaptoethanol	JJ	O
concentration	NN	O
is	VBZ	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
.	.	O
A	DT	O
related	JJ	O
aspect	NN	O
of	IN	O
this	DT	O
invention	NN	O
is	VBZ	O
a	DT	O
medium	NN	O
including	VBG	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
albumin	NN	O
,	,	O
minerals	NNS	O
,	,	O
lipids	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
,	,	O
and	CC	O
lithium	NN	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
define	VB	O
culture	NN	O
conditions	NNS	O
for	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
that	WDT	O
are	VBP	O
as	RB	O
defined	VBN	O
as	IN	O
possible	JJ	O
,	,	O
to	TO	O
allow	VB	O
the	DT	O
highest	JJS	O
percentage	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
to	TO	O
continue	VB	O
to	TO	O
proliferate	VB	O
and	CC	O
be	VB	O
maintained	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
Other	JJ	O
objects	NNS	O
,	,	O
features	NNS	O
and	CC	O
advantages	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
become	VB	O
apparent	JJ	O
from	IN	O
the	DT	O
following	JJ	O
specification	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
SEVERAL	NNP	O
VIEWS	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
illustrates	VBZ	O
optimization	NN	O
of	IN	O
physiochemical	JJ	O
conditions	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
growth	NN	O
;	:	O
effects	NNS	O
of	IN	O
altering	VBG	O
(	(	O
a	DT	O
)	)	O
pH	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
osmolarity	NN	O
,	,	O
and	CC	O
(	(	O
c	NN	O
)	)	O
atmospheric	JJ	O
environment	NN	O
on	IN	O
cell	NN	O
proliferation	NN	O
,	,	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
and	CC	O
spontaneous	JJ	O
differentiation	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
.	.	O
For	IN	O
cell	NN	O
proliferation	NN	O
and	CC	O
spontaneous	JJ	O
differentiation	NN	O
experiments	NNS	O
,	,	O
3×105	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
in	IN	O
triplicate	NN	O
wells	NNS	O
and	CC	O
analyzed	VBD	O
after	IN	O
7	CD	O
days	NNS	O
of	IN	O
growth	NN	O
.	.	O
For	IN	O
cloning	VBG	O
efficiency	NN	O
experiments	NNS	O
,	,	O
5000	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
in	IN	O
triplicate	NN	O
wells	NNS	O
and	CC	O
analyzed	VBD	O
after	IN	O
14	CD	O
days	NNS	O
of	IN	O
growth	NN	O
.	.	O
For	IN	O
pH	NN	O
experiments	NNS	O
,	,	O
osmolarity	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
330	CD	O
mOsMol	NN	O
and	CC	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
5	CD	O
%	NN	O
CO2/95	NNP	O
%	NN	O
Air	NNP	O
.	.	O
For	IN	O
osmolarity	NN	O
experiments	NNS	O
,	,	O
pH	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
7.2	CD	O
,	,	O
and	CC	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
5	CD	O
%	NN	O
CO2/95	NNP	O
%	NN	O
Air	NNP	O
.	.	O
For	IN	O
gas	NN	O
atmosphere	NN	O
experiments	NNS	O
,	,	O
pH	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
7.2	CD	O
,	,	O
and	CC	O
osmolarity	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
350±1-5	JJ	O
mOsMol	NN	O
.	.	O
A	DT	O
minimum	NN	O
of	IN	O
three	CD	O
independent	JJ	O
replicates	NNS	O
(	(	O
in	IN	O
triplicate	NN	O
)	)	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
parameter	NN	O
.	.	O
Data	NNS	O
are	VBP	O
presented	VBN	O
+/−SEM	NNP	O
.	.	O
*=significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
standard	JJ	O
conditions	NNS	O
for	IN	O
each	DT	O
parameter	NN	O
(	(	O
pH	JJ	O
7.0	CD	O
,	,	O
osmolarity	NN	O
330	CD	O
mOsMol	NN	O
,	,	O
atmosphere	RB	O
5	CD	O
%	NN	O
CO2/20	NNP	O
%	NN	O
O2	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
shows	NNS	O
growth	NN	O
curves	NNS	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
versus	NN	O
conditioned	VBD	O
medium	NN	O
(	(	O
CM	NNP	O
)	)	O
that	WDT	O
are	VBP	O
plotted	VBN	O
over	IN	O
three	CD	O
passages	NNS	O
starting	VBG	O
with	IN	O
an	DT	O
equivalent	JJ	O
number	NN	O
of	IN	O
cells	NNS	O
at	IN	O
day	NN	O
0	CD	O
for	IN	O
each	DT	O
passage	NN	O
(	(	O
5×105	CD	O
cells	NNS	O
)	)	O
;	:	O
for	IN	O
each	DT	O
passage	NN	O
,	,	O
cell	NN	O
counts	NNS	O
are	VBP	O
reported	VBN	O
(	(	O
1×105	CD	O
cells	NNS	O
)	)	O
from	IN	O
triplicate	NN	O
wells	NNS	O
at	IN	O
day	NN	O
3	CD	O
and	CC	O
day	NN	O
7	CD	O
;	:	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
third	JJ	O
passage	NN	O
,	,	O
cells	NNS	O
from	IN	O
triplicate	NN	O
wells	NNS	O
were	VBD	O
collected	VBN	O
an	DT	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell-specific	NN	O
markers	NNS	O
.	.	O
In	IN	O
eight	CD	O
replicates	NNS	O
of	IN	O
this	DT	O
experiment	NN	O
using	VBG	O
four	CD	O
different	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
cells	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
three	CD	O
passages	NNS	O
was	VBD	O
always	RB	O
greater	JJR	O
in	IN	O
TeSR1	NNP	O
than	IN	O
in	IN	O
conditioned	JJ	O
medium	NN	O
.	.	O
In	IN	O
the	DT	O
same	JJ	O
replicates	NNS	O
,	,	O
the	DT	O
percentage	NN	O
of	IN	O
cells	NNS	O
expressing	VBG	O
ES	NNP	O
cell	NN	O
markers	NNS	O
in	IN	O
TeSR1	NNP	O
was	VBD	O
either	RB	O
higher	JJR	O
than	IN	O
or	CC	O
equivalent	JJ	O
to	TO	O
the	DT	O
percentage	NN	O
in	IN	O
conditioned	JJ	O
medium	NN	O
.	.	O
CM	NNP	O
,	,	O
conditioned	VBD	O
medium	NN	O
.	.	O
FIGS	NNP	O
.	.	O
3A-D	JJ	O
show	NN	O
a	DT	O
graphical	JJ	O
presentation	NN	O
of	IN	O
FACS	NNP	O
data	NNS	O
showing	VBG	O
the	DT	O
high	JJ	O
level	NN	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
human	JJ	O
ES	NNP	O
cell	NN	O
culture	NN	O
grown	VBN	O
in	IN	O
CM	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
3	CD	O
A	DT	O
and	CC	O
C	NNP	O
)	)	O
and	CC	O
TeSR1	NNP	O
medium	NN	O
(	(	O
FIGS	NNP	O
.	.	O
3	CD	O
B	NNP	O
and	CC	O
D	NNP	O
)	)	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
expression	NN	O
of	IN	O
Oct-4	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
3	CD	O
A	DT	O
and	CC	O
B	NNP	O
)	)	O
and	CC	O
SSEA-4	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
3	CD	O
C	NNP	O
and	CC	O
D	NNP	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
is	VBZ	O
a	DT	O
graphical	JJ	O
representation	NN	O
of	IN	O
data	NNS	O
showing	VBG	O
that	IN	O
the	DT	O
medium	NN	O
described	VBD	O
here	RB	O
results	NNS	O
in	IN	O
robust	JJ	O
growth	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
.	.	O
Specifically	RB	O
,	,	O
what	WP	O
is	VBZ	O
shown	VBN	O
is	VBZ	O
growth	NN	O
curve	NN	O
analysis	NN	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1	NNP	O
(	(	O
positive	JJ	O
control	NN	O
)	)	O
,	,	O
and	CC	O
TeSR1	NNP	O
minus	VBD	O
the	DT	O
following	JJ	O
individual	JJ	O
components	NNS	O
:	:	O
TGFβ	NNP	O
,	,	O
pipecolic	JJ	O
acid	NN	O
(	(	O
PA	NNP	O
)	)	O
,	,	O
GABA	NNP	O
,	,	O
LiCl	NNP	O
and	CC	O
bFGF	NN	O
,	,	O
and	CC	O
TeSR1	NNP	O
minus	VBP	O
all	DT	O
five	CD	O
growth	NN	O
factors	NNS	O
(	(	O
TeSR1−ALL	NNP	O
or	CC	O
negative	JJ	O
control	NN	O
)	)	O
;	:	O
3×105	CD	O
cells	NNS	O
were	VBD	O
plated	VBN	O
at	IN	O
day	NN	O
0	CD	O
of	IN	O
each	DT	O
passage	NN	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
from	IN	O
experimental	JJ	O
work	NN	O
described	VBD	O
here	RB	O
below	IN	O
.	.	O
This	DT	O
shows	VBZ	O
that	IN	O
the	DT	O
omission	NN	O
of	IN	O
each	DT	O
component	NN	O
from	IN	O
the	DT	O
medium	NN	O
results	NNS	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
differentiated	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
culture	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
,	,	O
and	CC	O
thus	RB	O
it	PRP	O
can	MD	O
be	VB	O
inferred	VBN	O
that	IN	O
the	DT	O
inverse	NN	O
is	VBZ	O
true	JJ	O
(	(	O
i.e.	FW	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
each	DT	O
component	NN	O
in	IN	O
the	DT	O
medium	NN	O
reduces	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
differentiated	JJ	O
cells	NNS	O
)	)	O
.	.	O
This	DT	O
is	VBZ	O
shown	VBN	O
through	IN	O
the	DT	O
percent	NN	O
expression	NN	O
of	IN	O
the	DT	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	CD	O
,	,	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1	NNP	O
,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components	NNS	O
:	:	O
TGFβ	NNP	O
,	,	O
PA	NNP	O
,	,	O
GABA	NNP	O
,	,	O
LiCl	NNP	O
and	CC	O
bFGF	NN	O
;	:	O
data	NNS	O
are	VBP	O
reported	VBN	O
+/−standard	JJ	O
deviation	NN	O
;	:	O
“	CC	O
*	VB	O
”	JJ	O
indicates	NNS	O
significant	JJ	O
difference	NN	O
(	(	O
t-test	JJ	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
TeSR1	NNP	O
.	.	O
FIG	NNP	O
.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
for	IN	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
SSEA-1	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
for	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1	NNP	O
,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components	NNS	O
:	:	O
TGFβ	NNP	O
,	,	O
pipecolic	JJ	O
acid	NN	O
(	(	O
PA	NNP	O
)	)	O
,	,	O
GABA	NNP	O
,	,	O
LiCl	NNP	O
and	CC	O
bFGF	NN	O
.	.	O
Triplicate	NNP	O
wells	NNS	O
of	IN	O
resulting	VBG	O
cells	NNS	O
were	VBD	O
analyzed	VBN	O
on	IN	O
day	NN	O
6	CD	O
of	IN	O
passage	NN	O
3	CD	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
markers	NNS	O
.	.	O
All	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
for	IN	O
the	DT	O
H1	NNP	O
cell	NN	O
line	NN	O
;	:	O
similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
for	IN	O
cell	NN	O
lines	NNS	O
H7	NNP	O
,	,	O
H9	NNP	O
and	CC	O
H14	NNP	O
.	.	O
Data	NNS	O
are	VBP	O
reported	VBN	O
±standard	JJ	O
deviation	NN	O
.	.	O
*	NN	O
,	,	O
significantly	RB	O
different	JJ	O
(	(	O
t-test	JJ	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
from	IN	O
TeSR1	NNP	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
FACS	NNP	O
analysis	NN	O
for	IN	O
human	JJ	O
pluripotency	NN	O
markers	NNS	O
Oct-4	NNP	O
,	,	O
and	CC	O
cell	NN	O
proliferation	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
complete	JJ	O
TeSR1	NNP	O
,	,	O
and	CC	O
TeSR1	NNP	O
minus	NNP	O
each	DT	O
of	IN	O
the	DT	O
following	VBG	O
individual	JJ	O
components	NNS	O
:	:	O
TGFβ	NNP	O
,	,	O
LiCl	NNP	O
,	,	O
bFGF	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
(	(	O
PA	NNP	O
)	)	O
and	CC	O
GABA	NNP	O
.	.	O
FIGS	NNP	O
.	.	O
8A-B	JJ	O
shows	VBZ	O
the	DT	O
karyotype	JJ	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
;	:	O
H9	NNP	O
(	(	O
a	DT	O
)	)	O
and	CC	O
H14	NNP	O
(	(	O
b	NN	O
)	)	O
cell	NN	O
lines	NNS	O
were	VBD	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
matrix	NN	O
for	IN	O
21	CD	O
and	CC	O
7	CD	O
passages	NNS	O
(	(	O
FIG	NNP	O
.	.	O
8A	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
subjected	VBN	O
to	TO	O
cytogenetic	JJ	O
analysis	NN	O
using	VBG	O
G-banding	NNP	O
(	(	O
FIG	NNP	O
.	.	O
8B	CD	O
)	)	O
;	:	O
20	CD	O
metaphase	NN	O
cells	NNS	O
from	IN	O
each	DT	O
cell	NN	O
line	NN	O
were	VBD	O
evaluated	VBN	O
.	.	O
A	DT	O
normal	JJ	O
karyotype	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
all	DT	O
cells	NNS	O
examined	VBN	O
.	.	O
FIG	NNP	O
.	.	O
9	CD	O
illustrates	NNS	O
pluripotency	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
maintained	VBD	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
;	:	O
H1	NNP	O
and	CC	O
H9	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
for	IN	O
11	CD	O
and	CC	O
20	CD	O
passages	NNS	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
injected	VBD	O
into	IN	O
the	DT	O
rear	JJ	O
leg	JJ	O
muscle	NN	O
of	IN	O
4-week-old	JJ	O
SCID-beige	JJ	O
mice	NN	O
.	.	O
Teratomas	NNP	O
exhibiting	VBG	O
complex	JJ	O
differentiation	NN	O
developed	VBN	O
in	IN	O
the	DT	O
mice	JJ	O
6-8	JJ	O
weeks	NNS	O
post-inoculation	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
bone	NN	O
,	,	O
H9	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
epithelial	JJ	O
acinar	NN	O
structure	NN	O
,	,	O
H1	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
epithelial	JJ	O
luminal	JJ	O
structure	NN	O
,	,	O
H9	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
d	NN	O
)	)	O
epithelial	JJ	O
luminal	JJ	O
structure	NN	O
,	,	O
H1	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
e	NN	O
)	)	O
cartilage	NN	O
,	,	O
H9	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
f	NN	O
)	)	O
cartilage	NN	O
with	IN	O
epithelial	JJ	O
structure	NN	O
,	,	O
H1	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
g	NN	O
)	)	O
rosettes	VBZ	O
of	IN	O
neural	JJ	O
epithelium	NN	O
,	,	O
H9	NNP	O
cell	NN	O
line	NN	O
,	,	O
(	(	O
h	NN	O
)	)	O
and	CC	O
loosely	RB	O
structured	JJ	O
mesenchyme	NN	O
,	,	O
H1	NNP	O
cell	NN	O
line	NN	O
;	:	O
scale	JJ	O
bar=100	NN	O
um	NN	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
shows	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
matrix	NN	O
composition	NN	O
on	IN	O
cell	NN	O
proliferation	NN	O
and	CC	O
differentiation	NN	O
,	,	O
as	IN	O
measured	VBN	O
by	IN	O
Oct-4	NNP	O
expression	NN	O
and	CC	O
cell	NN	O
proliferation	NN	O
.	.	O
CVFL	NNP	O
refers	NNS	O
to	TO	O
the	DT	O
Matrigel™	NNP	O
substitute	NN	O
,	,	O
which	WDT	O
contains	VBZ	O
human	JJ	O
products	NNS	O
or	CC	O
recombinant	JJ	O
proteins	NNS	O
,	,	O
including	VBG	O
collagen	NN	O
(	(	O
C	NNP	O
)	)	O
,	,	O
vitronectin	FW	O
(	(	O
V	NNP	O
)	)	O
,	,	O
fibronectin	NN	O
(	(	O
F	NNP	O
)	)	O
and	CC	O
laminin	$	O
(	(	O
L	NNP	O
)	)	O
that	WDT	O
support	NN	O
cell	NN	O
growth	NN	O
and	CC	O
prevent	NN	O
differentiation	NN	O
.	.	O
These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
all	DT	O
four	CD	O
matrix	NN	O
components	NNS	O
are	VBP	O
not	RB	O
necessary	JJ	O
to	TO	O
support	VB	O
cell	NN	O
growth	NN	O
and	CC	O
prevent	NN	O
differentiation	NN	O
.	.	O
FIG	NNP	O
.	.	O
11	CD	O
shows	NNS	O
representative	JJ	O
morphology	NN	O
and	CC	O
FACS	NNP	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
defined	JJ	O
,	,	O
feeder-independent	JJ	O
conditions	NNS	O
.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
5	CD	O
passages	NNS	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
and	CC	O
then	RB	O
photographed	VBD	O
at	IN	O
magnifications	NNS	O
of	IN	O
2×	CD	O
(	(	O
a	DT	O
)	)	O
,	,	O
4×	CD	O
(	(	O
b	NN	O
)	)	O
,	,	O
and	CC	O
10×	CD	O
(	(	O
c	NN	O
)	)	O
using	VBG	O
phase	NN	O
contrast	NN	O
microscopy	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
internal	JJ	O
(	(	O
Oct-4	NNP	O
)	)	O
or	CC	O
cell	NN	O
surface	NN	O
(	(	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
Tra	NNP	O
1-81	CD	O
)	)	O
markers	NNS	O
after	IN	O
11	CD	O
passages	NNS	O
of	IN	O
culture	NN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
(	(	O
d-g	JJ	O
)	)	O
.	.	O
The	DT	O
level	NN	O
of	IN	O
undifferentiation	NN	O
is	VBZ	O
identified	VBN	O
as	IN	O
90	CD	O
%	NN	O
or	CC	O
greater	JJR	O
based	VBN	O
on	IN	O
percent	NN	O
positive	JJ	O
cell	NN	O
marker	NN	O
expression	NN	O
listed	VBN	O
in	IN	O
parentheses	NNS	O
and	CC	O
data	NNS	O
presented	VBN	O
are	VBP	O
from	IN	O
the	DT	O
H1	NNP	O
cell	NN	O
line	NN	O
.	.	O
Similar	JJ	O
results	NNS	O
were	VBD	O
obtained	VBN	O
using	VBG	O
the	DT	O
H9	NNP	O
cell	NN	O
line	NN	O
with	IN	O
16	CD	O
passages	NNS	O
of	IN	O
culture	NN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
.	.	O
FIG	NNP	O
.	.	O
12	CD	O
illustrates	VBZ	O
the	DT	O
absence	NN	O
of	IN	O
sialic	JJ	O
acid	JJ	O
contamination	NN	O
in	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
defined	JJ	O
conditions	NNS	O
.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
grown	VBN	O
under	IN	O
different	JJ	O
conditions	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
LC-MS	NNP	O
for	IN	O
the	DT	O
sialic	JJ	O
acids	NNS	O
Neu5Ac	NNP	O
and	CC	O
Neu5Gc	NNP	O
:	:	O
(	(	O
a	DT	O
)	)	O
the	DT	O
common	JJ	O
form	NN	O
,	,	O
NeuAc	NNP	O
was	VBD	O
found	VBN	O
abundantly	RB	O
expressed	VBN	O
on	IN	O
cells	NNS	O
regardless	RB	O
of	IN	O
culture	NN	O
conditions	NNS	O
with	IN	O
peak	JJ	O
intensities	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
1-3×108	JJ	O
(	(	O
traces	NNS	O
autoscaled	VBN	O
)	)	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
the	DT	O
non-human	JJ	O
Neu5Gc	NNP	O
was	VBD	O
found	VBN	O
on	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
grown	VBN	O
under	IN	O
standard	NN	O
(	(	O
conditioned	JJ	O
medium	NN	O
)	)	O
conditions	NNS	O
(	(	O
peak	JJ	O
intensity	NN	O
off	IN	O
scale	NN	O
at	IN	O
5×105	CD	O
)	)	O
,	,	O
it	PRP	O
was	VBD	O
reduced	VBN	O
but	CC	O
detectable	JJ	O
in	IN	O
partially	RB	O
humanized	VBN	O
conditions	NNS	O
with	IN	O
peak	JJ	O
intensity	NN	O
of	IN	O
4×104	CD	O
,	,	O
and	CC	O
no	DT	O
detectable	JJ	O
Neu5Gc	NNP	O
was	VBD	O
found	VBN	O
on	IN	O
cells	NNS	O
grown	VBN	O
in	IN	O
fully	RB	O
humanized	VBN	O
conditions	NNS	O
.	.	O
Growth	NNP	O
conditions	NNS	O
key	NN	O
:	:	O
Standard	NNP	O
Conditions=mouse	NNP	O
embryonic	JJ	O
fibroblast	NN	O
conditioned	VBD	O
media	NNS	O
on	IN	O
Matrigel	NNP	O
(	(	O
orange	NN	O
)	)	O
.	.	O
Partially	RB	O
Humanized=TeSR1	NNP	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
(	(	O
green	JJ	O
)	)	O
,	,	O
Fully	NNP	O
Humanized=TeSR1	NNP	O
medium	NN	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
(	(	O
blue	JJ	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
13	CD	O
shows	NNS	O
representative	JJ	O
morphology	NN	O
,	,	O
RT-PCR	NNP	O
and	CC	O
FACS	NNP	O
analysis	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
derived	VBN	O
and	CC	O
maintained	VBN	O
in	IN	O
defined	JJ	O
,	,	O
feeder-independent	JJ	O
culture	NN	O
conditions	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
WA	$	O
16	CD	O
cells	NNS	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
for	IN	O
16	CD	O
passages	NNS	O
were	VBD	O
photographed	VBN	O
at	IN	O
4×	CD	O
magnification	NN	O
using	VBG	O
phase	NN	O
contrast	NN	O
microscopy	NN	O
(	(	O
scale	JJ	O
bar	NN	O
,	,	O
100	CD	O
μm	NN	O
)	)	O
;	:	O
(	(	O
b	NN	O
)	)	O
RT-PCR	NNP	O
analysis	NN	O
of	IN	O
total	JJ	O
RNA	NNP	O
isolated	VBD	O
from	IN	O
control	NN	O
cells	NNS	O
(	(	O
H1	NNP	O
)	)	O
or	CC	O
newly	RB	O
derived	VBN	O
cell	NN	O
lines	NNS	O
(	(	O
WA15	NNP	O
and	CC	O
WA16	NNP	O
)	)	O
,	,	O
primer	JJ	O
sets	NNS	O
for	IN	O
pluripotency	NN	O
markers	NNS	O
(	(	O
Oct-4	NNP	O
,	,	O
Nanog	NNP	O
,	,	O
Rex1	NNP	O
,	,	O
hTERT	NN	O
)	)	O
and	CC	O
a	DT	O
housekeeping	NN	O
gene	NN	O
(	(	O
β-actin	JJ	O
)	)	O
were	VBD	O
analyzed	VBN	O
with	IN	O
(	(	O
+	NN	O
)	)	O
or	CC	O
without	IN	O
(	(	O
−	NN	O
)	)	O
RNA	NNP	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
WA15	NNP	O
cells	NNS	O
were	VBD	O
FACS	NNP	O
analyzed	VBD	O
after	IN	O
18	CD	O
passages	NNS	O
for	IN	O
internal	JJ	O
(	(	O
Oct-4	NNP	O
)	)	O
or	CC	O
cell	NN	O
surface	NN	O
(	(	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
Tra	NNP	O
1-81	CD	O
)	)	O
markers	NNS	O
.	.	O
Percentage	NN	O
of	IN	O
positive	JJ	O
cells	NNS	O
is	VBZ	O
listed	VBN	O
in	IN	O
parentheses	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
14A-B	JJ	O
illustrates	VBZ	O
the	DT	O
karyotype	NN	O
of	IN	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
derived	VBN	O
and	CC	O
maintained	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
for	IN	O
5	CD	O
months	NNS	O
(	(	O
FIG	NNP	O
.	.	O
14A	CD	O
)	)	O
were	VBD	O
subjected	VBN	O
to	TO	O
cytogenetic	JJ	O
analysis	NN	O
using	VBG	O
G-banding	NNP	O
(	(	O
FIG	NNP	O
.	.	O
14B	CD	O
)	)	O
;	:	O
twenty	JJ	O
metaphase	NN	O
cells	NNS	O
from	IN	O
each	DT	O
of	IN	O
the	DT	O
cell	NN	O
lines	NNS	O
were	VBD	O
evaluated	VBN	O
:	:	O
(	(	O
a	DT	O
)	)	O
a	DT	O
normal	JJ	O
46XY	CD	O
karyotype	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
all	DT	O
WA15	NNP	O
cells	NNS	O
,	,	O
while	IN	O
(	(	O
b	NN	O
)	)	O
all	DT	O
20	CD	O
WA16	NNP	O
cells	NNS	O
demonstrated	VBD	O
a	DT	O
47XXY	CD	O
karyotype	NN	O
.	.	O
FIG	NNP	O
.	.	O
15	CD	O
illustrates	VBZ	O
the	DT	O
growth	NN	O
of	IN	O
hES	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
mTeSR1	NN	O
with	IN	O
five	CD	O
different	JJ	O
concentrations	NNS	O
of	IN	O
beta	NN	O
mercaptoethanol	NN	O
(	(	O
βME	NNP	O
)	)	O
.	.	O
ES03-DL1-K	NNP	O
were	VBD	O
grown	VBN	O
for	IN	O
one	CD	O
to	TO	O
five	CD	O
passages	NNS	O
,	,	O
visualized	VBN	O
(	(	O
a	DT	O
)	)	O
,	,	O
counted	VBN	O
to	TO	O
determine	VB	O
proliferation	NN	O
and	CC	O
cloning	VBG	O
efficiency	NN	O
(	(	O
b	NN	O
)	)	O
,	,	O
and	CC	O
stained	VBD	O
using	VBG	O
Trypan	NNP	O
Blue	NNP	O
for	IN	O
Oct-4	NNP	O
and	CC	O
SSEA-4	NNP	O
to	TO	O
identify	VB	O
differentiation	NN	O
status	NN	O
of	IN	O
the	DT	O
cells	NNS	O
(	(	O
c	NN	O
)	)	O
.	.	O
The	DT	O
treatment	NN	O
concentrations	NNS	O
consisted	VBD	O
of	IN	O
0	CD	O
,	,	O
1.75	CD	O
,	,	O
3.5	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
μL	NN	O
βME/500	NNP	O
mL	NN	O
of	IN	O
total	JJ	O
TeSR1	NNP	O
media	NNS	O
.	.	O
Results	NNS	O
shown	VBN	O
are	VBP	O
the	DT	O
mean	NN	O
from	IN	O
growth	NN	O
in	IN	O
3	CD	O
wells/treatment	NN	O
.	.	O
This	DT	O
experiment	NN	O
was	VBD	O
repeated	VBN	O
multiple	JJ	O
times	NNS	O
both	DT	O
with	IN	O
ES03-DL1-K	NNP	O
and	CC	O
H9-WA09	NNP	O
cells	NNS	O
with	IN	O
similar	JJ	O
results	NNS	O
.	.	O
FIG	NNP	O
.	.	O
16	CD	O
illustrates	VBZ	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
culture	NN	O
and	CC	O
maintain	NN	O
iPS	NN	O
cells	NNS	O
.	.	O
Here	RB	O
pluripotent	JJ	O
cells	NNS	O
were	VBD	O
generated	VBN	O
from	IN	O
two	CD	O
iPS	NN	O
cell	NN	O
lines	NNS	O
,	,	O
each	DT	O
having	VBG	O
gone	VBN	O
through	IN	O
at	IN	O
least	JJS	O
10	CD	O
passages	NNS	O
in	IN	O
modified	JJ	O
TeSR1	NNP	O
medium	NN	O
.	.	O
(	(	O
A	DT	O
)	)	O
Flow	NNP	O
cytometry	NN	O
data	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
iPS	NN	O
cell	NN	O
line	NN	O
IMR90	NNP	O
,	,	O
cultured	VBD	O
for	IN	O
at	IN	O
least	JJS	O
10	CD	O
passages	NNS	O
in	IN	O
mTeSR1	NN	O
,	,	O
maintained	VBD	O
greater	JJR	O
than	IN	O
95	CD	O
%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells	NNS	O
.	.	O
(	(	O
B	NNP	O
)	)	O
flow	VBP	O
cytometry	NN	O
data	NNS	O
indicates	VBZ	O
that	IN	O
the	DT	O
vector-free	JJ	O
iPS	NN	O
cell	NN	O
line	NN	O
iPS-DF-19-9	NN	O
,	,	O
cultured	VBN	O
for	IN	O
at	IN	O
least	JJS	O
16	CD	O
passages	NNS	O
in	IN	O
mTeSR1	NN	O
,	,	O
maintained	VBD	O
more	JJR	O
than	IN	O
98	CD	O
%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells	NNS	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Currently	NNP	O
,	,	O
large	JJ	O
scale	NN	O
culturing	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
(	(	O
embryonic	JJ	O
and	CC	O
induced	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
)	)	O
for	IN	O
use	NN	O
in	IN	O
regenerative	JJ	O
medicine	NN	O
and	CC	O
drug	NN	O
discovery	NN	O
applications	NNS	O
is	VBZ	O
a	DT	O
major	JJ	O
challenge	NN	O
in	IN	O
biomedical	JJ	O
research	NN	O
and	CC	O
the	DT	O
pharmaceutical	JJ	O
industry	NN	O
.	.	O
To	TO	O
overcome	VB	O
this	DT	O
bottleneck	NN	O
,	,	O
stem	NN	O
cell	JJ	O
culture	NN	O
conditions	NNS	O
,	,	O
including	VBG	O
medium	NN	O
composition	NN	O
,	,	O
and	CC	O
culturing	VBG	O
processes	NNS	O
must	MD	O
become	VB	O
robust	JJ	O
,	,	O
reproducible	JJ	O
,	,	O
and	CC	O
capable	JJ	O
of	IN	O
generating	VBG	O
sufficient	JJ	O
numbers	NNS	O
of	IN	O
cells	NNS	O
while	IN	O
still	RB	O
maintaining	VBG	O
a	DT	O
stable	JJ	O
stem	NN	O
cell	NN	O
phenotype	NN	O
.	.	O
To	TO	O
meet	VB	O
this	DT	O
challenge	NN	O
,	,	O
the	DT	O
inventors	NNS	O
describe	VBP	O
here	RB	O
multiple	JJ	O
culture	NN	O
conditions	NNS	O
and	CC	O
media	NNS	O
,	,	O
which	WDT	O
permit	VBP	O
the	DT	O
indefinite	JJ	O
culture	NN	O
and	CC	O
robust	JJ	O
proliferation	NN	O
of	IN	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
with	IN	O
continued	JJ	O
expression	NN	O
of	IN	O
characteristic	JJ	O
pluripotency	NN	O
markers	NNS	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
media	NNS	O
described	VBN	O
are	VBP	O
prepared	VBN	O
in	IN	O
the	DT	O
complete	JJ	O
absence	NN	O
of	IN	O
both	DT	O
feeder	NN	O
cells	NNS	O
and	CC	O
conditioned	JJ	O
medium	NN	O
.	.	O
As	IN	O
described	VBN	O
here	RB	O
,	,	O
the	DT	O
defined	JJ	O
culture	NN	O
conditions	NNS	O
and	CC	O
media	NNS	O
are	VBP	O
suitable	JJ	O
for	IN	O
use	NN	O
with	IN	O
primate	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
Pluripotent	NNP	O
cells	NNS	O
express	VBP	O
one	CD	O
or	CC	O
more	JJR	O
pluripotent	JJ	O
cell-specific	JJ	O
marker	NN	O
,	,	O
such	JJ	O
as	IN	O
Oct-4	NNP	O
,	,	O
SSEA-3	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
Tra	NNP	O
1-81	CD	O
.	.	O
They	PRP	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
human	JJ	O
ES	NNP	O
cells	NNS	O
(	(	O
e.g.	NN	O
,	,	O
H1	NNP	O
,	,	O
H7	NNP	O
,	,	O
H9	NNP	O
and	CC	O
H14	NNP	O
)	)	O
,	,	O
iPS	JJ	O
cells	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
iPS-Foreskin	JJ	O
and	CC	O
iPS-IMR90	JJ	O
)	)	O
,	,	O
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
iPS-DF19-9	JJ	O
,	,	O
iPS-DF4-3	JJ	O
,	,	O
and	CC	O
iPS-DF6-9	NN	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
all	DT	O
available	JJ	O
through	IN	O
WiCell®	NNP	O
International	NNP	O
Stem	NNP	O
Cell	NNP	O
(	(	O
WISC	NNP	O
)	)	O
Bank	NNP	O
(	(	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
.	.	O
iPS	NN	O
cells	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Yu	NNP	B
J.	NNP	I
et	FW	I
al	NN	I
.	.	I
Science	NN	I
,	,	I
318	CD	I
(	(	I
5858	CD	I
)	)	I
,	,	I
pp	NN	I
.	.	I
1917-1920	CD	I
(	(	I
2007	CD	I
)	)	I
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Yu	NNP	B
J.	NNP	I
et	FW	I
al	NN	I
.	.	I
Science	NN	I
,	,	I
324	CD	I
(	(	I
5928	CD	I
)	)	I
,	,	I
pp	NN	I
.	.	I
797-801	CD	I
(	(	I
2009	CD	I
)	)	I
,	,	O
both	DT	O
of	IN	O
these	DT	O
references	NNS	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
For	IN	O
some	DT	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
including	VBG	O
iPS	NN	O
and	CC	O
vector-free	JJ	O
iPS	NN	O
cells	NNS	O
,	,	O
certificate	NN	O
of	IN	O
analyses	NNS	O
for	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
on	IN	O
growth	NN	O
matrix	NN	O
using	VBG	O
the	DT	O
fully	RB	O
defined	VBN	O
medium	NN	O
disclosed	VBN	O
here	RB	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
WISC	NNP	O
website	NN	O
.	.	O
Additional	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
disease	VB	O
model	NN	O
cell	NN	O
lines	NNS	O
and	CC	O
genetically	RB	O
modified	VBN	O
lines	NNS	O
containing	VBG	O
marker	NN	O
genes	NNS	O
.	.	O
In	IN	O
many	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
culture	NN	O
conditions	NNS	O
and	CC	O
media	NNS	O
are	VBP	O
entirely	RB	O
free	JJ	O
of	IN	O
non-human	JJ	O
animal	NN	O
products	NNS	O
and	CC	O
all	DT	O
proteins	NNS	O
used	VBN	O
are	VBP	O
of	IN	O
human	JJ	O
origin	NN	O
.	.	O
The	DT	O
development	NN	O
of	IN	O
these	DT	O
media	NNS	O
and	CC	O
culture	NN	O
conditions	NNS	O
make	VBP	O
possible	JJ	O
the	DT	O
derivation	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
in	IN	O
defined	JJ	O
and	CC	O
controlled	JJ	O
conditions	NNS	O
without	IN	O
direct	JJ	O
or	CC	O
indirect	JJ	O
exposure	NN	O
to	TO	O
non-human	JJ	O
animal	JJ	O
cells	NNS	O
of	IN	O
any	DT	O
kind	NN	O
.	.	O
Also	RB	O
,	,	O
the	DT	O
media	NNS	O
and	CC	O
culture	NN	O
conditions	NNS	O
described	VBD	O
here	RB	O
enable	JJ	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
which	WDT	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
non-human	JJ	O
cells	NNS	O
or	CC	O
a	DT	O
to	TO	O
medium	NN	O
in	IN	O
which	WDT	O
animal	JJ	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
media	NNS	O
disclosed	VBD	O
here	RB	O
permit	VBZ	O
the	DT	O
culture	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
primate	NN	O
and	CC	O
preferably	RB	O
human	JJ	O
ES	NNP	O
and	CC	O
iPS	JJ	O
cells	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
medium	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
animal	JJ	O
products	NNS	O
or	CC	O
proteins	NNS	O
.	.	O
This	DT	O
medium	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
to	TO	O
support	VB	O
undifferentiated	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
proliferation	NN	O
through	IN	O
at	IN	O
least	JJS	O
twenty-five	JJ	O
passages	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
firm	JJ	O
evidence	NN	O
that	IN	O
it	PRP	O
will	MD	O
support	VB	O
such	JJ	O
cultures	NNS	O
indefinitely	RB	O
.	.	O
A	DT	O
suitable	JJ	O
medium	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
supporting	VBG	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
human	JJ	O
ES	NNP	O
and	CC	O
iPS	NN	O
cell	NN	O
lines	NNS	O
,	,	O
and	CC	O
derived	VBD	O
using	VBG	O
the	DT	O
media	NNS	O
described	VBD	O
herein	RB	O
after	IN	O
as	IN	O
“	JJ	O
new	JJ	O
lines	NNS	O
”	NN	O
.	.	O
These	DT	O
lines	NNS	O
have	VBP	O
passed	VBN	O
through	IN	O
more	JJR	O
than	IN	O
ten	JJ	O
passages	NNS	O
in	IN	O
culture	NN	O
.	.	O
In	IN	O
the	DT	O
past	NN	O
,	,	O
use	NN	O
of	IN	O
conditioned	JJ	O
medium	NN	O
has	VBZ	O
sometimes	RB	O
been	VBN	O
referred	VBN	O
to	TO	O
as	IN	O
creating	VBG	O
“	JJ	O
feeder-free	JJ	O
”	JJ	O
culture	NN	O
conditions	NNS	O
.	.	O
This	DT	O
phrase	NN	O
is	VBZ	O
a	DT	O
misnomer	NN	O
,	,	O
since	IN	O
feeder	NN	O
cells	NNS	O
of	IN	O
some	DT	O
type	NN	O
are	VBP	O
still	RB	O
needed	VBN	O
to	TO	O
condition	VB	O
the	DT	O
“	NN	O
conditioned	VBD	O
medium.	JJ	O
”	NNP	O
As	IN	O
described	NN	O
here	RB	O
,	,	O
culture	NN	O
conditions	NNS	O
permit	VBP	O
the	DT	O
“	NNP	O
feeder-independent	JJ	O
”	JJ	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
By	IN	O
“	JJ	O
feeder-independent	JJ	O
”	NN	O
it	PRP	O
is	VBZ	O
meant	VBN	O
that	IN	O
no	DT	O
feeder	NN	O
cells	NNS	O
of	IN	O
any	DT	O
kind	NN	O
,	,	O
human	NN	O
or	CC	O
animal	NN	O
,	,	O
are	VBP	O
needed	VBN	O
anywhere	RB	O
in	IN	O
the	DT	O
process	NN	O
and	CC	O
are	VBP	O
neither	RB	O
required	VBN	O
for	IN	O
culture	NN	O
nor	CC	O
to	TO	O
condition	VB	O
the	DT	O
medium	NN	O
.	.	O
Feeder-independent	JJ	O
conditions	NNS	O
do	VBP	O
not	RB	O
require	VB	O
feeder	NN	O
cells	NNS	O
at	IN	O
all	DT	O
for	IN	O
any	DT	O
purpose	NN	O
.	.	O
A	DT	O
defined	JJ	O
and	CC	O
humanized	JJ	O
medium	NN	O
for	IN	O
the	DT	O
culture	NN	O
and	CC	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
typically	RB	O
includes	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
lipids	NNS	O
,	,	O
an	DT	O
energy	NN	O
source	NN	O
such	JJ	O
as	IN	O
glucose	NN	O
,	,	O
minerals	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
growth	NN	O
factors	NNS	O
and	CC	O
other	JJ	O
components	NNS	O
.	.	O
As	IN	O
a	DT	O
supplement	NN	O
to	TO	O
support	VB	O
cell	NN	O
growth	NN	O
,	,	O
stem	NN	O
cell	NN	O
media	NNS	O
have	VBP	O
included	VBN	O
serum	NN	O
from	IN	O
one	CD	O
source	NN	O
or	CC	O
another	DT	O
.	.	O
Also	RB	O
,	,	O
previously	RB	O
it	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
FGF	NNP	O
plus	CC	O
a	DT	O
serum	JJ	O
replacement	NN	O
additive	JJ	O
permits	VBZ	O
the	DT	O
cultivation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
without	IN	O
serum	NN	O
.	.	O
The	DT	O
serum	JJ	O
replacement	NN	O
additive	NN	O
can	MD	O
be	VB	O
a	DT	O
commercially	RB	O
available	JJ	O
product	NN	O
sold	VBN	O
for	IN	O
that	DT	O
purpose	NN	O
or	CC	O
can	MD	O
be	VB	O
a	DT	O
formulated	JJ	O
mixture	NN	O
of	IN	O
proteins	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
serum	VB	O
albumin	NN	O
,	,	O
vitamins	NNS	O
,	,	O
minerals	NNS	O
,	,	O
a	DT	O
transferrin	NN	O
or	CC	O
a	DT	O
transferrin	JJ	O
substitute	NN	O
,	,	O
and	CC	O
insulin	NN	O
or	CC	O
an	DT	O
insulin	JJ	O
substitute	NN	O
.	.	O
The	DT	O
albumin	NN	O
,	,	O
insulin	NN	O
and	CC	O
transferrin	NN	O
may	MD	O
be	VB	O
recombinant	JJ	O
proteins	NNS	O
.	.	O
This	DT	O
serum	JJ	O
replacement	NN	O
additive	NN	O
may	MD	O
also	RB	O
be	VB	O
supplemented	VBN	O
with	IN	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
selenium	NN	O
and	CC	O
a	DT	O
mixture	NN	O
of	IN	O
lipids	NNS	O
.	.	O
Preferably	RB	O
,	,	O
a	DT	O
defined	JJ	O
serum	NN	O
replacement	NN	O
mix	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
lieu	NN	O
of	IN	O
serum	NN	O
from	IN	O
any	DT	O
source	NN	O
in	IN	O
culturing	VBG	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
to	TO	O
avoid	VB	O
variation	NN	O
in	IN	O
serum	NN	O
constituents	NNS	O
and	CC	O
to	TO	O
use	VB	O
media	NNS	O
that	WDT	O
are	VBP	O
as	RB	O
defined	VBN	O
as	IN	O
possible	JJ	O
.	.	O
Other	JJ	O
growth	NN	O
factors	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
advantageous	JJ	O
additives	NNS	O
to	TO	O
the	DT	O
culture	NN	O
medium	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
gamma-aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
,	,	O
pipecolic	JJ	O
acid	NN	O
(	(	O
PA	NNP	O
)	)	O
,	,	O
lithium	JJ	O
chloride	NN	O
(	(	O
LiCl	NNP	O
)	)	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
(	(	O
TGFβ	NNP	O
)	)	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
found	VBN	O
that	IN	O
TGFβ	NNP	O
may	MD	O
not	RB	O
be	VB	O
needed	VBN	O
when	WRB	O
increasing	VBG	O
levels	NNS	O
of	IN	O
FGF	NNP	O
are	VBP	O
added	VBN	O
to	TO	O
the	DT	O
medium	NN	O
.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
other	JJ	O
lithium	NN	O
salts	NNS	O
can	MD	O
substitute	VB	O
for	IN	O
LiCl	NNP	O
in	IN	O
the	DT	O
cell	NN	O
culture	NN	O
medium	NN	O
.	.	O
These	DT	O
may	MD	O
include	VB	O
lithium	NN	O
salts	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
anion	NN	O
includes	VBZ	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
chloride	VB	O
,	,	O
bromide	VB	O
,	,	O
carbonate	NN	O
,	,	O
citrate	NN	O
,	,	O
sulfate	NN	O
,	,	O
or	CC	O
other	JJ	O
biologically	RB	O
compatible	JJ	O
monovalent	NN	O
anion	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
US	NNP	O
2004/0028656	CD	O
and	CC	O
WO	NNP	O
2008/055224	CD	O
)	)	O
.	.	O
To	TO	O
avoid	VB	O
the	DT	O
need	NN	O
for	IN	O
a	DT	O
fibroblast	JJ	O
feeder	NN	O
layer	NN	O
,	,	O
previously	RB	O
thought	VBN	O
to	TO	O
be	VB	O
necessary	JJ	O
to	TO	O
maintain	VB	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
(	(	O
ES	NNP	O
and	CC	O
iPS	VB	O
cells	NNS	O
)	)	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
it	PRP	O
is	VBZ	O
reported	VBN	O
here	RB	O
that	IN	O
combining	VBG	O
the	DT	O
use	NN	O
of	IN	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
FGF	NNP	O
(	(	O
10	CD	O
to	TO	O
1000	CD	O
ng/ml	NN	O
)	)	O
together	RB	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
Li	NNP	O
and	CC	O
TGFβ	NNP	O
,	,	O
will	MD	O
enable	VB	O
a	DT	O
medium	NN	O
to	TO	O
support	VB	O
long	JJ	O
term	NN	O
(	(	O
at	IN	O
least	JJS	O
three	CD	O
passages	NNS	O
,	,	O
and	CC	O
suitably	RB	O
170	CD	O
passages	NNS	O
)	)	O
undifferentiated	JJ	O
stem	NN	O
cell	NN	O
growth	NN	O
.	.	O
The	DT	O
combination	NN	O
of	IN	O
these	DT	O
additives	NNS	O
has	VBZ	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
sufficient	JJ	O
to	TO	O
maintain	VB	O
the	DT	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
indefinitely	RB	O
without	IN	O
exposure	NN	O
to	TO	O
either	DT	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media	NNS	O
.	.	O
These	DT	O
additives	NNS	O
are	VBP	O
demonstrably	RB	O
sufficient	JJ	O
.	.	O
However	RB	O
,	,	O
all	DT	O
of	IN	O
them	PRP	O
may	MD	O
not	RB	O
be	VB	O
necessary	JJ	O
for	IN	O
every	DT	O
medium	NN	O
formulation	NN	O
.	.	O
By	IN	O
selective	JJ	O
deletion	NN	O
of	IN	O
these	DT	O
additives	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
empirically	RB	O
determined	VBN	O
if	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
them	PRP	O
is	VBZ	O
not	RB	O
required	VBN	O
to	TO	O
achieve	VB	O
this	DT	O
result	NN	O
for	IN	O
a	DT	O
given	VBN	O
medium	NN	O
.	.	O
However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
clear	JJ	O
that	IN	O
the	DT	O
combination	NN	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
enable	VB	O
a	DT	O
variety	NN	O
of	IN	O
media	NNS	O
that	WDT	O
will	MD	O
support	VB	O
the	DT	O
long-term	JJ	O
culture	NN	O
and	CC	O
proliferation	NN	O
of	IN	O
undifferentiated	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
medium	NN	O
.	.	O
These	DT	O
additives	NNS	O
are	VBP	O
subject	JJ	O
to	TO	O
some	DT	O
variation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
GABA	NNP	O
is	VBZ	O
believed	VBN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
GABA	NNP	O
receptor	NN	O
and	CC	O
the	DT	O
scientific	JJ	O
literature	NN	O
includes	VBZ	O
the	DT	O
identification	NN	O
of	IN	O
several	JJ	O
molecules	NNS	O
which	WDT	O
are	VBP	O
agonists	NNS	O
of	IN	O
that	DT	O
same	JJ	O
receptor	NN	O
and	CC	O
might	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
GABA	NNP	O
in	IN	O
the	DT	O
medium	NN	O
as	IN	O
an	DT	O
equivalent	NN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
believed	VBN	O
that	IN	O
PA	NNP	O
also	RB	O
interacts	VBZ	O
with	IN	O
the	DT	O
GABA	NNP	O
receptor	NN	O
.	.	O
While	IN	O
both	DT	O
PA	NNP	O
and	CC	O
GABA	NNP	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
helpful	JJ	O
in	IN	O
the	DT	O
medium	NN	O
at	IN	O
the	DT	O
concentrations	NNS	O
used	VBN	O
here	RB	O
,	,	O
it	PRP	O
is	VBZ	O
also	RB	O
envisioned	VBN	O
that	IN	O
one	CD	O
or	CC	O
the	DT	O
other	JJ	O
of	IN	O
these	DT	O
constituents	NNS	O
could	MD	O
be	VB	O
increased	VBN	O
in	IN	O
concentration	NN	O
to	TO	O
obviate	VB	O
the	DT	O
need	NN	O
for	IN	O
the	DT	O
other	JJ	O
.	.	O
The	DT	O
FGF	NNP	O
in	IN	O
higher	JJR	O
concentrations	NNS	O
(	(	O
40	CD	O
to	TO	O
100	CD	O
ng/ml	NN	O
)	)	O
seems	VBZ	O
to	TO	O
obviate	VB	O
the	DT	O
need	NN	O
for	IN	O
feeder	NN	O
cells	NNS	O
.	.	O
The	DT	O
preferred	JJ	O
FGF	NNP	O
is	VBZ	O
bFGF	VBN	O
,	,	O
also	RB	O
referred	VBD	O
to	TO	O
as	IN	O
FGF2	NNP	O
,	,	O
but	CC	O
other	JJ	O
FGFs	NNP	O
,	,	O
including	VBG	O
at	IN	O
least	JJS	O
FGF4	NNP	O
,	,	O
FGF9	NNP	O
,	,	O
FGF17	NNP	O
,	,	O
and	CC	O
FGF18	NNP	O
,	,	O
will	MD	O
suffice	VB	O
for	IN	O
this	DT	O
purpose	NN	O
as	RB	O
well	RB	O
.	.	O
Other	JJ	O
FGFs	NNP	O
may	MD	O
also	RB	O
work	VB	O
,	,	O
even	RB	O
if	IN	O
at	IN	O
higher	JJR	O
concentrations	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
empirically	RB	O
determined	VBN	O
by	IN	O
researchers	NNS	O
.	.	O
Initial	JJ	O
subjective	JJ	O
screens	NNS	O
performed	VBN	O
by	IN	O
the	DT	O
inventors	NNS	O
identified	VBD	O
several	JJ	O
growth	NN	O
factors	NNS	O
,	,	O
chosen	NNS	O
based	VBN	O
on	IN	O
the	DT	O
receptors	NNS	O
expressed	VBN	O
by	IN	O
the	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
,	,	O
as	IN	O
having	VBG	O
positive	JJ	O
effects	NNS	O
on	IN	O
undifferentiated	JJ	O
proliferation	NN	O
.	.	O
Of	IN	O
these	DT	O
,	,	O
bFGF	NN	O
,	,	O
LiCl	NNP	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
TGFβ	NNP	O
were	VBD	O
ultimately	RB	O
included	VBN	O
in	IN	O
TeSR1	NNP	O
.	.	O
For	IN	O
each	DT	O
of	IN	O
the	DT	O
multiple	NN	O
cell	NN	O
lines	NNS	O
tested	VBN	O
,	,	O
the	DT	O
proliferation	NN	O
rate	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
cells	NNS	O
maintaining	VBG	O
expression	NN	O
of	IN	O
characteristic	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
markers	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
TeSR1	NNP	O
than	IN	O
in	IN	O
control	NN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
fibroblast-conditioned	JJ	O
medium	NN	O
and	CC	O
removal	NN	O
of	IN	O
any	DT	O
one	CD	O
of	IN	O
these	DT	O
five	CD	O
factors	NNS	O
decreased	JJ	O
culture	NN	O
performance	NN	O
.	.	O
Some	DT	O
of	IN	O
these	DT	O
data	NNS	O
are	VBP	O
illustrated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
,	,	O
which	WDT	O
shows	VBZ	O
that	IN	O
cultures	NNS	O
grown	VBN	O
in	IN	O
media	NNS	O
with	IN	O
any	DT	O
one	CD	O
of	IN	O
these	DT	O
constituents	NNS	O
omitted	VBD	O
exhibited	VBD	O
a	DT	O
lesser	JJR	O
percentage	NN	O
of	IN	O
cells	NNS	O
which	WDT	O
remained	VBD	O
undifferentiated	JJ	O
as	IN	O
compared	VBN	O
to	TO	O
cultures	NNS	O
with	IN	O
all	DT	O
five	CD	O
of	IN	O
these	DT	O
medium	NN	O
constituents	NNS	O
included	VBD	O
.	.	O
Note	NN	O
that	IN	O
Oct-4	NNP	O
,	,	O
SSEA-1	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	NNS	O
are	VBP	O
all	DT	O
cell	NN	O
surface	NN	O
markers	NNS	O
or	CC	O
transcription	NN	O
factors	NNS	O
(	(	O
Oct-4	NNP	O
)	)	O
which	WDT	O
are	VBP	O
used	VBN	O
to	TO	O
track	VB	O
the	DT	O
differentiation	NN	O
status	NN	O
of	IN	O
stem	NN	O
cells	NNS	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
illustrates	NNS	O
similar	JJ	O
trials	NNS	O
in	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
demonstrated	VBN	O
that	IN	O
,	,	O
over	IN	O
multiple	JJ	O
passages	NNS	O
,	,	O
undifferentiated	JJ	O
cell	NN	O
proliferation	NN	O
was	VBD	O
the	DT	O
highest	JJS	O
when	WRB	O
all	PDT	O
these	DT	O
constituents	NNS	O
together	RB	O
were	VBD	O
in	IN	O
the	DT	O
culture	NN	O
medium	NN	O
.	.	O
The	DT	O
inventors	NNS	O
also	RB	O
found	VBD	O
it	PRP	O
advantageous	JJ	O
to	TO	O
include	VB	O
in	IN	O
the	DT	O
culture	NN	O
vessel	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
a	DT	O
biological	JJ	O
matrix	NN	O
.	.	O
One	CD	O
such	JJ	O
material	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
used	VBN	O
previously	RB	O
is	VBZ	O
Matrigel™	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
an	DT	O
artificial	JJ	O
basement	NN	O
matrix	NN	O
of	IN	O
mouse	NN	O
cell	NN	O
origin	NN	O
,	,	O
which	WDT	O
is	VBZ	O
supplied	VBN	O
as	IN	O
a	DT	O
commercial	JJ	O
product	NN	O
free	JJ	O
of	IN	O
mouse	NN	O
cells	NNS	O
.	.	O
However	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
Matrigel	NNP	O
introduces	NNS	O
into	IN	O
the	DT	O
culture	NN	O
a	DT	O
material	NN	O
which	WDT	O
is	VBZ	O
poorly	RB	O
defined	VBN	O
and	CC	O
includes	VBZ	O
material	NN	O
of	IN	O
murine	NN	O
origin	NN	O
.	.	O
Accordingly	RB	O
,	,	O
also	RB	O
described	VBN	O
here	RB	O
is	VBZ	O
how	WRB	O
to	TO	O
create	VB	O
a	DT	O
biological	JJ	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
that	WDT	O
can	MD	O
substitute	VB	O
completely	RB	O
for	IN	O
the	DT	O
Matrigel	NNP	O
.	.	O
This	DT	O
matrix	NN	O
is	VBZ	O
composed	VBN	O
of	IN	O
a	DT	O
blend	NN	O
of	IN	O
four	CD	O
human	JJ	O
proteins	NNS	O
:	:	O
collagen	NN	O
isolated	VBD	O
from	IN	O
human	JJ	O
placenta	NN	O
,	,	O
fibronectin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma	NN	O
,	,	O
vitronectin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma	NN	O
or	CC	O
from	IN	O
a	DT	O
recombinant	JJ	O
source	NN	O
,	,	O
and	CC	O
laminin	RB	O
isolated	VBN	O
from	IN	O
human	JJ	O
placenta	NN	O
.	.	O
Other	JJ	O
extracellular	JJ	O
matrices	NNS	O
may	MD	O
be	VB	O
suitable	JJ	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
which	WDT	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
proteoglycan	JJ	O
,	,	O
entactin	JJ	O
,	,	O
heparan	JJ	O
sulfate	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
alone	RB	O
or	CC	O
in	IN	O
various	JJ	O
combinations	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
extracellular	JJ	O
matrices	NNS	O
may	MD	O
include	VB	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
Geltrex™	NNP	O
.	.	O
The	DT	O
major	JJ	O
components	NNS	O
of	IN	O
Geltrex™	NNP	O
matrix	NNP	O
include	VBP	O
laminin	NN	O
,	,	O
collagen	NN	O
IV	NNP	O
,	,	O
entactin	NN	O
,	,	O
and	CC	O
heparin	JJ	O
sulfate	NN	O
proteoglycan	NN	O
.	.	O
Also	RB	O
suitable	JJ	O
are	VBP	O
human	JJ	O
plasma	NN	O
fibronectin	NN	O
,	,	O
recombinant	JJ	O
human	JJ	O
plasma	NN	O
fibronectin	NN	O
,	,	O
human	JJ	O
cellular	JJ	O
fibronectin	NN	O
,	,	O
recombinant	JJ	O
human	JJ	O
cellular	JJ	O
fibronectin	NN	O
,	,	O
and	CC	O
synthetic	JJ	O
fibronectin	NN	O
in	IN	O
combination	NN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
other	JJ	O
matrix	NN	O
,	,	O
such	JJ	O
as	IN	O
collagen	NN	O
.	.	O
Preferred	NNP	O
matrices	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
collagen	NN	O
,	,	O
fibronectin	NN	O
,	,	O
vitronectin	NN	O
,	,	O
and	CC	O
laminin	VBZ	O
derived	VBN	O
matrices	NNS	O
.	.	O
The	DT	O
combination	NN	O
of	IN	O
these	DT	O
four	CD	O
human	NN	O
proteins	NNS	O
is	VBZ	O
sufficient	JJ	O
,	,	O
but	CC	O
the	DT	O
use	NN	O
of	IN	O
all	DT	O
four	CD	O
may	MD	O
not	RB	O
be	VB	O
necessary	JJ	O
to	TO	O
support	VB	O
the	DT	O
growth	NN	O
and	CC	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
the	DT	O
experimental	JJ	O
results	NNS	O
depicted	VBD	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
such	JJ	O
a	DT	O
matrix	NN	O
without	IN	O
one	CD	O
of	IN	O
vitronectin	NN	O
,	,	O
fibronectin	NN	O
,	,	O
or	CC	O
laminin	NN	O
,	,	O
but	CC	O
including	VBG	O
the	DT	O
other	JJ	O
three	CD	O
matrix	NN	O
proteins	NNS	O
,	,	O
does	VBZ	O
support	VB	O
the	DT	O
culture	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
with	IN	O
some	DT	O
loss	NN	O
of	IN	O
purity	NN	O
in	IN	O
the	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
the	DT	O
ES	NNP	O
or	CC	O
iPS	NN	O
cell	NN	O
culture	NN	O
.	.	O
Likewise	RB	O
,	,	O
it	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
such	JJ	O
a	DT	O
matrix	NN	O
without	IN	O
two	CD	O
of	IN	O
vitronectin	NN	O
,	,	O
fibronectin	NN	O
or	CC	O
laminin	NN	O
,	,	O
does	VBZ	O
support	VB	O
the	DT	O
culture	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
with	IN	O
some	DT	O
loss	NN	O
of	IN	O
purity	NN	O
in	IN	O
the	DT	O
state	NN	O
of	IN	O
differentiation	NN	O
of	IN	O
the	DT	O
ES	NNP	O
or	CC	O
iPS	NN	O
cell	NN	O
culture	NN	O
.	.	O
Suitable	JJ	O
matrix	NN	O
protein	NN	O
combinations	NNS	O
include	VBP	O
collagen	NN	O
and	CC	O
fibronectin	NN	O
,	,	O
collagen	NN	O
and	CC	O
vitronectin	NN	O
,	,	O
and	CC	O
collagen	NN	O
and	CC	O
laminin	NN	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
making	VBG	O
the	DT	O
matrix	NN	O
for	IN	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
growth	NN	O
is	VBZ	O
described	VBN	O
in	IN	O
the	DT	O
examples	NNS	O
below	IN	O
.	.	O
To	TO	O
arrive	VB	O
at	IN	O
the	DT	O
above-listed	JJ	O
medium	NN	O
additives	NNS	O
,	,	O
the	DT	O
inventors	NNS	O
methodically	RB	O
tested	VBD	O
over	IN	O
80	CD	O
individual	JJ	O
media	NNS	O
components	NNS	O
,	,	O
including	VBG	O
growth	NN	O
factors	NNS	O
.	.	O
While	IN	O
some	DT	O
of	IN	O
the	DT	O
additives	NNS	O
seemed	VBD	O
,	,	O
at	IN	O
least	JJS	O
for	IN	O
a	DT	O
few	JJ	O
passages	NNS	O
,	,	O
to	TO	O
support	VB	O
the	DT	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
,	,	O
many	JJ	O
failed	VBD	O
in	IN	O
subsequent	JJ	O
passages	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
The	DT	O
inventors	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
identify	VB	O
combinations	NNS	O
of	IN	O
specific	JJ	O
growth	NN	O
factors	NNS	O
useful	JJ	O
in	IN	O
the	DT	O
medium	NN	O
described	VBN	O
in	IN	O
the	DT	O
examples	NNS	O
below	IN	O
.	.	O
Also	RB	O
,	,	O
through	IN	O
methodical	JJ	O
testing	NN	O
,	,	O
the	DT	O
inventors	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
varying	VBG	O
the	DT	O
concentration	NN	O
of	IN	O
β-mercaptoethanol	NNP	O
(	(	O
BME	NNP	O
)	)	O
in	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
,	,	O
when	WRB	O
culturing	VBG	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
BME	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
various	JJ	O
parameters	NNS	O
in	IN	O
a	DT	O
culture	NN	O
medium	NN	O
that	WDT	O
affects	VBZ	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
pluripotent	NN	O
cells	NNS	O
in	IN	O
a	DT	O
positive	JJ	O
manner	NN	O
.	.	O
Specifically	RB	O
,	,	O
when	WRB	O
BME	NNP	O
was	VBD	O
either	RB	O
omitted	VBN	O
or	CC	O
used	VBN	O
in	IN	O
a	DT	O
concentration	NN	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
(	(	O
between	IN	O
about	RB	O
0	CD	O
to	TO	O
about	IN	O
0.1	CD	O
mM	NN	O
)	)	O
in	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
,	,	O
the	DT	O
cells	NNS	O
continued	VBD	O
to	TO	O
proliferate	VB	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
15	CD	O
a-b	JJ	O
)	)	O
with	IN	O
minimal	JJ	O
to	TO	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
differentiation	NN	O
status	NN	O
of	IN	O
the	DT	O
cells	NNS	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
15	CD	O
c	NN	O
)	)	O
.	.	O
Most	JJS	O
notably	RB	O
,	,	O
however	RB	O
,	,	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
increased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
and	CC	O
preferably	RB	O
20	CD	O
%	NN	O
,	,	O
30	CD	O
%	NN	O
,	,	O
40	CD	O
%	NN	O
,	,	O
50	CD	O
%	NN	O
,	,	O
60	CD	O
%	NN	O
,	,	O
70	CD	O
%	NN	O
,	,	O
80	CD	O
%	NN	O
,	,	O
90	CD	O
%	NN	O
,	,	O
and	CC	O
100	CD	O
%	NN	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
15	CD	O
a	DT	O
)	)	O
in	IN	O
comparison	NN	O
with	IN	O
pluripotent	JJ	O
cells	NNS	O
cultured	VBN	O
in	IN	O
the	DT	O
same	JJ	O
medium	NN	O
having	VBG	O
higher	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	NNS	O
BME	NNP	O
.	.	O
Accordingly	RB	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
a	DT	O
medium	NN	O
is	VBZ	O
disclosed	VBN	O
for	IN	O
increasing	VBG	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
pluripotent	NN	O
cells	NNS	O
in	IN	O
culture	NN	O
,	,	O
wherein	VBP	O
the	DT	O
medium	NN	O
contains	VBZ	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
,	,	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
,	,	O
and	CC	O
lithium	NN	O
,	,	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
stem	NN	O
cells	NNS	O
grown	VBN	O
in	IN	O
the	DT	O
medium	NN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
culture	NN	O
passages	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
increases	VBZ	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
compared	VBN	O
to	TO	O
the	DT	O
medium	NN	O
containing	VBG	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.1	CD	O
mM	NN	O
BME	NNP	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
a	DT	O
method	NN	O
is	VBZ	O
disclosed	VBN	O
for	IN	O
increasing	VBG	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
cells	NNS	O
in	IN	O
culture	NN	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
through	IN	O
culturing	VBG	O
the	DT	O
primate	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
on	IN	O
a	DT	O
matrix	NN	O
in	IN	O
a	DT	O
medium	NN	O
without	IN	O
feeder	NN	O
cells	NNS	O
or	CC	O
conditioned	VBN	O
media	NNS	O
,	,	O
the	DT	O
medium	NN	O
comprising	NN	O
salts	NNS	O
,	,	O
vitamins	NNS	O
,	,	O
amino	JJ	O
acids	NNS	O
,	,	O
glucose	NN	O
,	,	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
,	,	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
mM	JJ	O
beta-mercaptoethanol	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
selected	VBN	O
from	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
,	,	O
and	CC	O
lithium	NN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
embodiment	NN	O
,	,	O
when	WRB	O
gamma-aminobutyric	JJ	O
acid	NN	O
,	,	O
pipecolic	JJ	O
acid	NN	O
,	,	O
lithium	NN	O
,	,	O
and	CC	O
transforming	VBG	O
growth	NN	O
factor	NN	O
beta	NN	O
are	VBP	O
added	VBN	O
in	IN	O
sufficient	JJ	O
amounts	NNS	O
to	TO	O
maintain	VB	O
the	DT	O
human	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
culture	NN	O
are	VBP	O
positive	JJ	O
for	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
through	IN	O
multiple	JJ	O
successive	JJ	O
culture	NN	O
passages	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
observation	NN	O
that	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
cultures	NNS	O
have	VBP	O
previously	RB	O
been	VBN	O
maintained	VBN	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
only	RB	O
when	WRB	O
cultured	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
fibroblast	JJ	O
feeder	NN	O
cells	NNS	O
or	CC	O
in	IN	O
conditioned	JJ	O
medium	NN	O
has	VBZ	O
led	VBN	O
to	TO	O
speculation	NN	O
that	IN	O
the	DT	O
fibroblasts	NNS	O
release	VBP	O
a	DT	O
factor	NN	O
into	IN	O
the	DT	O
medium	NN	O
,	,	O
which	WDT	O
acts	VBZ	O
to	TO	O
inhibit	VB	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
differentiation	NN	O
.	.	O
The	DT	O
data	NN	O
presented	VBD	O
here	RB	O
demonstrate	VB	O
that	IN	O
this	DT	O
not	RB	O
the	DT	O
case	NN	O
.	.	O
However	RB	O
,	,	O
whatever	WDT	O
effect	NN	O
fibroblast	NN	O
feeder	NN	O
cells	NNS	O
have	VBP	O
on	IN	O
culture	NN	O
medium	NN	O
,	,	O
it	PRP	O
is	VBZ	O
now	RB	O
clear	JJ	O
that	IN	O
the	DT	O
media	NNS	O
described	VBN	O
below	IN	O
will	MD	O
substitute	VB	O
for	IN	O
that	DT	O
effect	NN	O
.	.	O
The	DT	O
media	NNS	O
described	VBD	O
below	RB	O
,	,	O
as	IN	O
defined	VBN	O
,	,	O
contain	VBP	O
no	DT	O
non-human	JJ	O
cells	NNS	O
,	,	O
and	CC	O
permit	VB	O
the	DT	O
long-term	JJ	O
culture	NN	O
of	IN	O
undifferentiated	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
This	DT	O
strategy	NN	O
enables	VBZ	O
the	DT	O
preparation	NN	O
of	IN	O
a	DT	O
“	NNP	O
humanized	VBN	O
”	NNP	O
medium	NN	O
and	CC	O
matrix	NN	O
to	TO	O
avoid	VB	O
any	DT	O
possible	JJ	O
concerns	NNS	O
about	IN	O
sub-cellular	JJ	O
products	NNS	O
of	IN	O
non-human	JJ	O
origin	NN	O
.	.	O
Table	JJ	O
1	CD	O
describes	VBZ	O
a	DT	O
defined	JJ	O
medium	NN	O
developed	VBN	O
by	IN	O
the	DT	O
inventors	NNS	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
medium	NN	O
components	NNS	O
and	CC	O
their	PRP$	O
preferred	JJ	O
concentrations	NNS	O
are	VBP	O
listed	VBN	O
in	IN	O
the	DT	O
table	NN	O
.	.	O
It	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
concentration	NN	O
ranges	VBZ	O
that	WDT	O
are	VBP	O
at	IN	O
least	JJS	O
10×	CD	O
higher	JJR	O
or	CC	O
10×	CD	O
lower	JJR	O
than	IN	O
the	DT	O
concentrations	NNS	O
listed	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
may	MD	O
be	VB	O
able	JJ	O
to	TO	O
support	VB	O
culture	NN	O
and	CC	O
derivation	NN	O
of	IN	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
The	DT	O
complete	JJ	O
medium	NN	O
is	VBZ	O
designated	VBN	O
TeSR1	NNP	O
.	.	O
The	DT	O
TeSR1	NNP	O
medium	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
DMEM/DF12	NNP	O
base	NN	O
,	,	O
supplemented	VBN	O
with	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
,	,	O
vitamins	NNS	O
,	,	O
antioxidants	NNS	O
,	,	O
trace	NN	O
minerals	NNS	O
,	,	O
specific	JJ	O
lipids	NNS	O
and	CC	O
cloned	JJ	O
growth	NN	O
factors	NNS	O
.	.	O
Based	VBN	O
on	IN	O
the	DT	O
formulation	NN	O
of	IN	O
TeSR1	NNP	O
in	IN	O
Table	NNP	O
1	CD	O
,	,	O
it	PRP	O
is	VBZ	O
expected	VBN	O
that	IN	O
a	DT	O
suitable	JJ	O
concentration	NN	O
range	NN	O
for	IN	O
a	DT	O
salt	NN	O
in	IN	O
the	DT	O
medium	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
100	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
vitamin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-05	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.5	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
an	DT	O
amino	NN	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-03	JJ	O
mM	NN	O
to	TO	O
about	IN	O
30	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
mineral	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-07	JJ	O
mM	NN	O
to	TO	O
about	IN	O
10.0	CD	O
E-02	JJ	O
mM	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
lipid	JJ	O
is	VBZ	O
from	IN	O
about	IN	O
8.0	CD	O
E-06	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-02	JJ	O
mM	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
glucose	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
mM	NNS	O
to	TO	O
about	IN	O
150	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
fibroblast	JJ	O
growth	NN	O
factor	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
ng/ml	NNS	O
to	TO	O
about	IN	O
1000	CD	O
ng/ml	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
10	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
pipecolic	JJ	O
acid	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-04	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-02	JJ	O
mM	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
lithium	NN	O
is	VBZ	O
from	IN	O
about	IN	O
0.1	CD	O
mM	NNS	O
to	TO	O
about	IN	O
10	CD	O
mM	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
a	DT	O
transforming	JJ	O
growth	NN	O
factor	NN	O
beta	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-09	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.0	CD	O
E-07	JJ	O
mM	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
insulin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
4.0	CD	O
E-04	JJ	O
mM	NN	O
to	TO	O
about	IN	O
4.0	CD	O
E-02	JJ	O
mM	NN	O
.	.	O
A	DT	O
suitable	JJ	O
range	NN	O
for	IN	O
transferrin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
1.0	CD	O
E-05	JJ	O
mM	NN	O
to	TO	O
about	IN	O
1.0	CD	O
E-03	JJ	O
mM	NN	O
.	.	O
Also	RB	O
,	,	O
a	DT	O
suitable	JJ	O
concentration	NN	O
range	NN	O
for	IN	O
albumin	NN	O
is	VBZ	O
from	IN	O
about	IN	O
2.0	CD	O
E-02	JJ	O
mM	NN	O
to	TO	O
about	IN	O
2.0	CD	O
mM	NNS	O
.	.	O
Because	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
(	(	O
HSA	NNP	O
)	)	O
is	VBZ	O
expensive	JJ	O
,	,	O
the	DT	O
inventors	NNS	O
routinely	RB	O
use	VBP	O
bovine	JJ	O
serum	NN	O
albumin	NN	O
(	(	O
BSA	NNP	O
)	)	O
as	IN	O
a	DT	O
less	RBR	O
costly	JJ	O
substitute	NN	O
.	.	O
Although	IN	O
the	DT	O
species	NNS	O
source	NN	O
of	IN	O
the	DT	O
albumin	NN	O
is	VBZ	O
different	JJ	O
,	,	O
BSA	NNP	O
in	IN	O
the	DT	O
TeSR	NNP	O
medium	NN	O
(	(	O
mTeSR1	NN	O
)	)	O
functions	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
its	PRP$	O
humanized	JJ	O
counterpart	NN	O
,	,	O
TeSR1	NNP	O
medium	NN	O
,	,	O
which	WDT	O
contains	VBZ	O
HSA	NNP	O
.	.	O
This	DT	O
humanized	JJ	O
version	NN	O
of	IN	O
TeSR	NNP	O
has	VBZ	O
been	VBN	O
renamed	VBN	O
and	CC	O
is	VBZ	O
currently	RB	O
marketed	VBN	O
as	IN	O
TeSR2	NNP	O
by	IN	O
Stem	NNP	O
Cell	NNP	O
Technologies	NNPS	O
(	(	O
Vancouver	NNP	O
,	,	O
BC	NNP	O
,	,	O
Canada	NNP	O
)	)	O
.	.	O
Also	RB	O
described	VBN	O
below	IN	O
is	VBZ	O
the	DT	O
derivation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
using	VBG	O
TeSR1	NNP	O
(	(	O
see	VB	O
Ludwig	NNP	B
T.	NNP	I
E.	NNP	I
et	FW	I
al	NN	I
.	.	I
Nat	NNP	I
.	.	I
Biotech	NNP	I
.	.	I
24	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
185-187	JJ	I
(	(	I
2006	CD	I
)	)	I
and	CC	O
related	JJ	O
Supplementary	NNP	O
results	NNS	O
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
)	)	O
.	.	O
The	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
,	,	O
such	JJ	O
as	IN	O
ES	NNP	O
and	CC	O
iPS	JJ	O
cells	NNS	O
,	,	O
disclosed	VBN	O
herein	NN	O
and	CC	O
provided	VBN	O
in	IN	O
the	DT	O
corresponding	JJ	O
Ludwig	NNP	O
(	(	O
2006	CD	O
)	)	O
paper	NN	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
,	,	O
conditioned	VBD	O
medium	NN	O
,	,	O
non-human	JJ	O
animal	NN	O
products	NNS	O
or	CC	O
non-human	JJ	O
animal	JJ	O
proteins	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
previously	RB	O
been	VBN	O
reported	VBN	O
that	IN	O
prior	JJ	O
human	JJ	O
ES	NNP	O
lines	NNS	O
exhibit	VBP	O
a	DT	O
sialic	JJ	O
acid	NN	O
form	NN	O
(	(	O
Neu5Gc	NNP	O
)	)	O
that	WDT	O
is	VBZ	O
not	RB	O
natively	RB	O
found	VBN	O
in	IN	O
human	JJ	O
cells	NNS	O
whether	IN	O
in	IN	O
culture	NN	O
or	CC	O
in	IN	O
the	DT	O
body	NN	O
.	.	O
Since	IN	O
the	DT	O
prior	JJ	O
human	JJ	O
ES	NNP	O
lines	NNS	O
acquired	VBD	O
the	DT	O
Neu5Gc	NNP	O
from	IN	O
culture	NN	O
conditions	NNS	O
including	VBG	O
murine	NN	O
components	NNS	O
,	,	O
the	DT	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
described	VBN	O
here	RB	O
are	VBP	O
and	CC	O
will	MD	O
be	VB	O
entirely	RB	O
free	JJ	O
of	IN	O
Neu5Gc	NNP	O
(	(	O
FIG	NNP	O
.	.	O
12	CD	O
)	)	O
.	.	O
The	DT	O
invention	NN	O
will	MD	O
be	VB	O
more	RBR	O
fully	RB	O
understood	JJ	O
upon	IN	O
consideration	NN	O
of	IN	O
the	DT	O
following	JJ	O
non-limiting	JJ	O
Examples	NNS	O
.	.	O
In	IN	O
the	DT	O
Examples	NNP	O
,	,	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
including	VBG	O
human	JJ	O
ES	NNP	O
cells	NNS	O
and	CC	O
iPS	JJ	O
cells	NNS	O
,	,	O
were	VBD	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
(	(	O
set	VBN	O
forth	NN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
)	)	O
and	CC	O
variations	NNS	O
of	IN	O
the	DT	O
medium	NN	O
where	WRB	O
certain	JJ	O
components	NNS	O
have	VBP	O
been	VBN	O
removed	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
specifically	RB	O
contemplated	VBN	O
that	IN	O
the	DT	O
methods	NNS	O
disclosed	VBN	O
are	VBP	O
suited	VBN	O
for	IN	O
primate	JJ	O
pluripotent	NN	O
cells	NNS	O
generally	RB	O
as	IN	O
pluripotent	NN	O
cells	NNS	O
,	,	O
regardless	RB	O
of	IN	O
their	PRP$	O
origin	NN	O
,	,	O
operate	NN	O
in	IN	O
substantially	RB	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
the	DT	O
disclosed	JJ	O
methods	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
media	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
here	RB	O
are	VBP	O
suitable	JJ	O
for	IN	O
culturing	VBG	O
primate	JJ	O
iPS	NN	O
cells	NNS	O
.	.	O
EXAMPLES	NNP	O
Inventors	NNS	O
used	VBD	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
H1	NNP	O
,	,	O
H7	NNP	O
,	,	O
H9	NNP	O
and	CC	O
H14	NNP	O
(	(	O
Thomson	NNP	B
,	,	I
J	NNP	I
.	.	I
A.	NN	I
et	CC	I
al	NN	I
.	.	I
Science	NN	I
282	CD	I
,	,	I
1145-1147	CD	I
(	(	I
1998	CD	I
)	)	I
)	)	O
in	IN	O
a	DT	O
program	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
media	NNS	O
optimization	NN	O
that	WDT	O
included	VBD	O
modifications	NNS	O
to	TO	O
the	DT	O
physiochemical	JJ	O
environment	NN	O
,	,	O
growth	NN	O
factor	NN	O
supplements	NNS	O
and	CC	O
matrix	JJ	O
components	NNS	O
.	.	O
To	TO	O
accomplish	VB	O
this	DT	O
,	,	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
H1	NNP	O
,	,	O
H7	NNP	O
,	,	O
H9	NNP	O
,	,	O
and	CC	O
H14	NNP	O
were	VBD	O
cultured	VBN	O
on	IN	O
Matrigel	NNP	O
(	(	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
in	IN	O
fibroblast-conditioned	JJ	O
medium	NN	O
as	IN	O
previously	RB	O
described	VBN	O
(	(	O
Xu	NNP	B
,	,	I
C.	NNP	I
et	CC	I
al	NN	I
.	.	I
Nature	NNP	I
Biotechnology	NNP	I
19	CD	I
,	,	I
971-974	CD	I
(	(	I
2001	CD	I
)	)	I
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
transitioned	VBN	O
into	IN	O
test	NN	O
media	NNS	O
by	IN	O
direct	JJ	O
passage	NN	O
from	IN	O
conditioned	VBN	O
medium	NN	O
.	.	O
Cultures	NNS	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
in	IN	O
clumps	NNS	O
at	IN	O
approximately	RB	O
weekly	JJ	O
intervals	NNS	O
onto	IN	O
Matrigel	NNP	O
or	CC	O
human	JJ	O
matrix-coated	JJ	O
plates	NNS	O
by	IN	O
exposure	NN	O
to	TO	O
dispase	VB	O
(	(	O
2.0	CD	O
or	CC	O
0.5	CD	O
mg/ml	NNS	O
respectively	RB	O
:	:	O
Invitrogen	NN	O
)	)	O
.	.	O
Following	VBG	O
7	CD	O
minutes	NNS	O
of	IN	O
dispase	NN	O
exposure	NN	O
,	,	O
cells	NNS	O
were	VBD	O
rinsed	VBN	O
3	CD	O
(	(	O
three	CD	O
)	)	O
times	NNS	O
on	IN	O
the	DT	O
plate	NN	O
with	IN	O
medium	NN	O
,	,	O
followed	VBN	O
by	IN	O
gentle	JJ	O
scraping	VBG	O
to	TO	O
collect	VB	O
.	.	O
Colonies	NNS	O
were	VBD	O
further	RB	O
broken	VBN	O
up	RP	O
by	IN	O
gentle	JJ	O
pipetting	NN	O
and	CC	O
then	RB	O
plated	VBD	O
.	.	O
The	DT	O
human	JJ	O
matrix-coated	JJ	O
plates	NNS	O
were	VBD	O
composed	VBN	O
of	IN	O
10	CD	O
μg/cm2	JJ	O
human	JJ	O
collagen	NN	O
IV	NNP	O
(	(	O
Sigma	NNP	O
or	CC	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
,	,	O
0.2	CD	O
μg/cm2	JJ	O
human	JJ	O
vitronectin	NN	O
(	(	O
Sigma	NNP	O
)	)	O
,	,	O
5	CD	O
μg/cm2	JJ	O
human	JJ	O
fibronectin	NN	O
(	(	O
Sigma	NNP	O
or	CC	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
and	CC	O
5	CD	O
μg/cm2	JJ	O
human	JJ	O
laminin	NN	O
(	(	O
Sigma	NNP	O
)	)	O
.	.	O
During	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
studies	NNS	O
we	PRP	O
successfully	RB	O
used	VBD	O
4	CD	O
lots	NNS	O
of	IN	O
fibronectin	NN	O
,	,	O
2	CD	O
lots	NNS	O
of	IN	O
collagen	NN	O
,	,	O
3	CD	O
lots	NNS	O
of	IN	O
laminin	NN	O
,	,	O
and	CC	O
3	CD	O
lots	NNS	O
of	IN	O
vitronectin	NN	O
.	.	O
For	IN	O
growth	NN	O
curve	NN	O
proliferation	NN	O
studies	NNS	O
,	,	O
3-5×105	JJ	O
cells	NNS	O
were	VBD	O
plated	VBN	O
on	IN	O
Day	NNP	O
0	CD	O
of	IN	O
each	DT	O
passage	NN	O
into	IN	O
conditioned	JJ	O
medium	NN	O
,	,	O
TeSR1	NNP	O
or	CC	O
TeSR1	NNP	O
minus	CC	O
the	DT	O
following	JJ	O
components	NNS	O
:	:	O
TGFβ	NNP	O
,	,	O
PA	NNP	O
,	,	O
GABA	NNP	O
,	,	O
LiCl	NNP	O
and	CC	O
bFGF	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
three	CD	O
passages	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
on	IN	O
Day	NNP	O
2-3	JJ	O
and	CC	O
Day	NNP	O
6-7	JJ	O
and	CC	O
counted	VBD	O
using	VBG	O
a	DT	O
Trypan	NNP	O
Blue	NNP	O
exclusion	NN	O
assay	NN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
passage	NN	O
three	CD	O
,	,	O
cells	NNS	O
were	VBD	O
individualized	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
trypsin/EDTA	NN	O
and	CC	O
were	VBD	O
analyzed	VBN	O
by	IN	O
FACS	NNP	O
for	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
markers	NNS	O
Oct-4	NNP	O
,	,	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
and	CC	O
Tra	NNP	O
1-81	JJ	O
as	IN	O
subsequently	RB	O
described	VBN	O
.	.	O
Specifically	RB	O
,	,	O
to	TO	O
optimize	VB	O
the	DT	O
physiochemical	JJ	O
environment	NN	O
,	,	O
human	JJ	O
ES	NNP	O
cells	NNS	O
with	IN	O
an	DT	O
EGFP	NNP	O
reporter	NN	O
gene	NN	O
and	CC	O
a	DT	O
neomycin	JJ	O
resistance	NN	O
cassette	NN	O
under	IN	O
control	NN	O
of	IN	O
the	DT	O
endogenous	JJ	O
Oct-4	JJ	O
gene	NN	O
were	VBD	O
utilized	VBN	O
for	IN	O
the	DT	O
physiochemical	JJ	O
optimization	NN	O
assays	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
G418	NNP	O
(	(	O
Invitrogen	NNP	O
)	)	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
assay	NN	O
to	TO	O
ensure	VB	O
a	DT	O
pure	JJ	O
stem	NN	O
cell	NN	O
population	NN	O
upon	IN	O
initiation	NN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
growth	NN	O
period	NN	O
,	,	O
cells	NNS	O
from	IN	O
independent	JJ	O
wells	NNS	O
were	VBD	O
individualized	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
trypsin/EDTA	NN	O
,	,	O
counted	VBN	O
and	CC	O
subjected	VBN	O
to	TO	O
FACS	NNP	O
analysis	NN	O
as	IN	O
subsequently	RB	O
described	VBN	O
.	.	O
To	TO	O
determine	VB	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
,	,	O
resulting	VBG	O
colonies	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
BCIP/NTB	NNP	O
alkaline	JJ	O
phosphatase	NN	O
substrate	JJ	O
kit	NN	O
IV	NNP	O
(	(	O
Vector	NNP	O
Laboratories	NNPS	O
)	)	O
and	CC	O
counted	VBN	O
.	.	O
Percentages	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
dividing	VBG	O
colony	NN	O
number	NN	O
obtained	VBN	O
by	IN	O
the	DT	O
initial	JJ	O
number	NN	O
of	IN	O
cells	NNS	O
plated	VBN	O
.	.	O
Our	PRP$	O
analysis	NN	O
of	IN	O
physiochemical	JJ	O
culture	NN	O
conditions	NNS	O
suggested	VBD	O
that	IN	O
undifferentiated	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
proliferation	NN	O
was	VBD	O
optimal	JJ	O
at	IN	O
a	DT	O
pH	NN	O
of	IN	O
7.2	CD	O
,	,	O
an	DT	O
osmolarity	NN	O
of	IN	O
350	CD	O
mOsMol	NN	O
and	CC	O
an	DT	O
atmosphere	NN	O
of	IN	O
10	CD	O
%	NN	O
CO2/5	NNP	O
%	NN	O
O2	NNP	O
(	(	O
FIG	NNP	O
.	.	O
1	CD	O
)	)	O
.	.	O
These	DT	O
conditions	NNS	O
were	VBD	O
used	VBN	O
for	IN	O
all	DT	O
subsequent	JJ	O
cultures	NNS	O
described	VBD	O
herein	NN	O
.	.	O
An	DT	O
initial	JJ	O
subjective	JJ	O
list	NN	O
of	IN	O
growth	NN	O
factors	NNS	O
was	VBD	O
selected	VBN	O
for	IN	O
testing	VBG	O
based	VBN	O
on	IN	O
receptors	NNS	O
expressed	VBN	O
by	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
.	.	O
(	(	O
See	VB	O
Sperger	NNP	B
,	,	I
J.	NNP	I
M.	NNP	I
et	FW	I
al	NN	I
.	.	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
100	CD	I
,	,	I
13350-13355	CD	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
Several	JJ	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
undifferentiated	JJ	O
proliferation	NN	O
.	.	O
Of	IN	O
these	DT	O
,	,	O
bFGF	NN	O
,	,	O
LiCl	NNP	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
and	CC	O
TGFβ	NNP	O
were	VBD	O
ultimately	RB	O
included	VBN	O
in	IN	O
TeSR1	NNP	O
.	.	O
To	TO	O
test	VB	O
the	DT	O
conditions	NNS	O
of	IN	O
the	DT	O
ES	NNP	O
cell	NN	O
colonies	NNS	O
and	CC	O
the	DT	O
suitability	NN	O
of	IN	O
the	DT	O
culture	NN	O
for	IN	O
the	DT	O
long-term	JJ	O
maintenance	NN	O
of	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
cultures	NNS	O
,	,	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
best	JJS	O
prior	JJ	O
medium	NN	O
condition	NN	O
,	,	O
which	WDT	O
,	,	O
in	IN	O
the	DT	O
inventor	NN	O
's	POS	O
hands	NNS	O
,	,	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
conditioned	JJ	O
medium	NN	O
.	.	O
It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
was	VBD	O
capable	JJ	O
of	IN	O
increasing	VBG	O
cellular	JJ	O
proliferation	NN	O
(	(	O
FIG	NNP	O
.	.	O
2	CD	O
)	)	O
and	CC	O
maintaining	VBG	O
the	DT	O
human	JJ	O
ES	NNP	O
cells	NNS	O
in	IN	O
such	JJ	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
that	WDT	O
over	IN	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
continued	VBD	O
to	TO	O
test	VB	O
positive	JJ	O
for	IN	O
Oct-4	NNP	O
even	RB	O
after	IN	O
long-term	JJ	O
culture	NN	O
(	(	O
FIG	NNP	O
.	.	O
3	LS	O
)	)	O
.	.	O
This	DT	O
represents	VBZ	O
the	DT	O
first	JJ	O
known	VBN	O
instance	NN	O
in	IN	O
which	WDT	O
any	DT	O
medium	NN	O
,	,	O
free	JJ	O
of	IN	O
both	DT	O
feeder	NN	O
cells	NNS	O
and	CC	O
conditioned	JJ	O
medium	NN	O
,	,	O
has	VBZ	O
maintained	VBN	O
undifferentiated	JJ	O
growth	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
such	JJ	O
that	IN	O
over	IN	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
cells	NNS	O
in	IN	O
the	DT	O
culture	NN	O
remain	NN	O
undifferentiated	JJ	O
.	.	O
Using	VBG	O
the	DT	O
media	NNS	O
and	CC	O
culture	NN	O
system	NN	O
described	VBD	O
here	RB	O
,	,	O
it	PRP	O
is	VBZ	O
now	RB	O
possible	JJ	O
to	TO	O
establish	VB	O
and	CC	O
maintain	VB	O
primate	JJ	O
pluripotent	JJ	O
stem	NN	O
cell	NN	O
lines	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
85	CD	O
to	TO	O
89	CD	O
%	NN	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
at	IN	O
least	JJS	O
91	CD	O
to	TO	O
99	CD	O
%	NN	O
undifferentiated	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
Several	JJ	O
factors	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
undifferentiated	JJ	O
proliferation	NN	O
.	.	O
Of	IN	O
these	DT	O
,	,	O
bFGF	NN	O
,	,	O
LiCl	NNP	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
,	,	O
and	CC	O
TGFβ	NNP	O
were	VBD	O
ultimately	RB	O
included	VBN	O
in	IN	O
TeSR1	NNP	O
.	.	O
Removal	NN	O
of	IN	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
five	CD	O
factors	NNS	O
significantly	RB	O
decreased	VBD	O
some	DT	O
parameter	NN	O
of	IN	O
culture	NN	O
performance	NN	O
,	,	O
but	CC	O
only	RB	O
the	DT	O
removal	NN	O
of	IN	O
bFGF	NN	O
consistently	RB	O
decreased	VBN	O
both	CC	O
the	DT	O
total	NN	O
cell	NN	O
number	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
cells	NNS	O
expressing	VBG	O
ES	NNP	O
cell	NN	O
markers	NNS	O
(	(	O
FIGS	NNP	O
.	.	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
)	)	O
.	.	O
When	WRB	O
exogenous	JJ	O
bFGF	NN	O
was	VBD	O
removed	VBN	O
,	,	O
some	DT	O
undifferentiated	JJ	O
cells	NNS	O
nonetheless	RB	O
persisted	VBD	O
through	IN	O
at	IN	O
least	JJS	O
three	CD	O
passages	NNS	O
(	(	O
FIGS	NNP	O
.	.	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
)	)	O
.	.	O
If	IN	O
all	DT	O
five	CD	O
factors	NNS	O
were	VBD	O
removed	VBN	O
,	,	O
however	RB	O
,	,	O
culture	NN	O
was	VBD	O
not	RB	O
sustainable	JJ	O
beyond	IN	O
the	DT	O
first	JJ	O
passage	NN	O
(	(	O
FIGS	NNP	O
.	.	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
)	)	O
.	.	O
While	IN	O
a	DT	O
medium	NN	O
with	IN	O
all	DT	O
of	IN	O
the	DT	O
above	JJ	O
constituents	NNS	O
is	VBZ	O
sufficient	JJ	O
and	CC	O
is	VBZ	O
preferred	VBN	O
,	,	O
not	RB	O
all	DT	O
of	IN	O
the	DT	O
components	NNS	O
are	VBP	O
necessary	JJ	O
for	IN	O
the	DT	O
successful	JJ	O
culture	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
amount	NN	O
of	IN	O
differentiated	JJ	O
cells	NNS	O
one	CD	O
is	VBZ	O
willing	JJ	O
to	TO	O
tolerate	VB	O
,	,	O
some	DT	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
medium	NN	O
can	MD	O
be	VB	O
omitted	VBN	O
,	,	O
particularly	RB	O
if	IN	O
the	DT	O
medium	NN	O
is	VBZ	O
only	RB	O
used	VBN	O
for	IN	O
a	DT	O
few	JJ	O
passages	NNS	O
.	.	O
To	TO	O
further	RBR	O
explore	RB	O
which	WDT	O
constituents	NNS	O
might	MD	O
be	VB	O
omitted	VBN	O
,	,	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
on	IN	O
variants	NNS	O
of	IN	O
the	DT	O
above	JJ	O
medium	NN	O
with	IN	O
differing	VBG	O
components	NNS	O
omitted	VBN	O
.	.	O
Two	CD	O
hundred	CD	O
thousand	NNS	O
cells	NNS	O
were	VBD	O
plated	VBN	O
and	CC	O
grown	VBN	O
for	IN	O
seven	CD	O
days	NNS	O
on	IN	O
each	DT	O
experimental	JJ	O
medium	NN	O
,	,	O
two	CD	O
wells	NNS	O
per	IN	O
treatment	NN	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
then	RB	O
assayed	VBN	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
transcription	NN	O
factor	NN	O
Oct-4	NNP	O
,	,	O
a	DT	O
recognized	VBN	O
marker	NN	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
.	.	O
The	DT	O
data	NN	O
from	IN	O
that	DT	O
experiment	NN	O
are	VBP	O
presented	VBN	O
graphically	RB	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
,	,	O
where	WRB	O
the	DT	O
numbers	NNS	O
of	IN	O
Oct-4	NNP	O
expressing	VBG	O
cells	NNS	O
in	IN	O
each	DT	O
experimental	JJ	O
medium	NN	O
are	VBP	O
presented	VBN	O
as	IN	O
a	DT	O
fraction	NN	O
of	IN	O
that	DT	O
from	IN	O
the	DT	O
preferred	JJ	O
medium	NN	O
TeSR1	NNP	O
.	.	O
Note	NN	O
that	IN	O
TGFβ	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
the	DT	O
least	JJS	O
necessary	JJ	O
component	NN	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
FGF	NNP	O
for	IN	O
short-term	JJ	O
culture	NN	O
.	.	O
Also	RB	O
,	,	O
note	NN	O
that	IN	O
omitting	VBG	O
other	JJ	O
constituents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
LiCl	NNP	O
,	,	O
bFGF	NN	O
,	,	O
PA	NNP	O
,	,	O
or	CC	O
GABA	NNP	O
)	)	O
does	VBZ	O
result	VB	O
in	IN	O
increased	JJ	O
percentages	NNS	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
culture	NN	O
.	.	O
The	DT	O
difference	NN	O
between	IN	O
the	DT	O
percentage	NN	O
of	IN	O
undifferentiated	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
omitted	JJ	O
constituent	NN	O
is	VBZ	O
quantitative	JJ	O
.	.	O
Regardless	RB	O
of	IN	O
the	DT	O
omitted	JJ	O
constituent	NN	O
,	,	O
the	DT	O
medium	NN	O
does	VBZ	O
work	VB	O
,	,	O
at	IN	O
least	JJS	O
to	TO	O
some	DT	O
degree	NN	O
for	IN	O
limited	JJ	O
cell	NN	O
passages	NNS	O
,	,	O
without	IN	O
each	DT	O
of	IN	O
the	DT	O
omitted	JJ	O
components	NNS	O
.	.	O
Cells	NNS	O
of	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
H1	NNP	O
,	,	O
H7	NNP	O
,	,	O
H9	NNP	O
and	CC	O
H14	NNP	O
cells	NNS	O
have	VBP	O
all	DT	O
proliferated	VBN	O
robustly	RB	O
in	IN	O
TeSR1	NNP	O
for	IN	O
11	CD	O
,	,	O
7	CD	O
,	,	O
25	CD	O
,	,	O
and	CC	O
17	CD	O
passages	NNS	O
respectively	RB	O
(	(	O
2-6	JJ	O
months	NNS	O
)	)	O
.	.	O
The	DT	O
karyotypes	NNS	O
were	VBD	O
confirmed	VBN	O
normal	JJ	O
for	IN	O
cell	NN	O
line	NN	O
H14	NNP	O
after	IN	O
7	CD	O
passages	NNS	O
and	CC	O
H9	NNP	O
after	IN	O
8	CD	O
and	CC	O
21	CD	O
passages	NNS	O
(	(	O
FIG	NNP	O
.	.	O
8	CD	O
)	)	O
.	.	O
Teratoma	NNP	O
formation	NN	O
was	VBD	O
confirmed	VBN	O
for	IN	O
H1	NNP	O
and	CC	O
H9	NNP	O
after	IN	O
11	CD	O
and	CC	O
20	CD	O
passages	NNS	O
,	,	O
respectively	RB	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
)	)	O
.	.	O
Initial	JJ	O
experiments	NNS	O
with	IN	O
TeSR1	NNP	O
medium	NN	O
were	VBD	O
all	DT	O
performed	VBN	O
on	IN	O
Matrigel	NNP	O
,	,	O
a	DT	O
basement	NN	O
membrane	NN	O
preparation	NN	O
extracted	VBD	O
from	IN	O
a	DT	O
murine	JJ	O
Englebreth-Holm-Swarm	JJ	O
sarcoma	NN	O
.	.	O
Matrigel	NNP	O
effectively	RB	O
supports	VBZ	O
long-term	JJ	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
TeSR1	NNP	O
medium	NN	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
a	DT	O
complex	JJ	O
mixture	NN	O
of	IN	O
murine	NN	O
proteins	NNS	O
and	CC	O
is	VBZ	O
a	DT	O
significant	JJ	O
source	NN	O
of	IN	O
variability	NN	O
in	IN	O
culture	NN	O
.	.	O
After	IN	O
screening	VBG	O
a	DT	O
variety	NN	O
of	IN	O
components	NNS	O
individually	RB	O
and	CC	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
inventors	NNS	O
developed	VBD	O
a	DT	O
new	JJ	O
matrix	JJ	O
material	NN	O
of	IN	O
human	JJ	O
origin	NN	O
composed	VBN	O
of	IN	O
the	DT	O
following	VBG	O
four	CD	O
proteins	NNS	O
:	:	O
1	CD	O
.	.	O
Collagen	NNP	O
(	(	O
isolated	VBN	O
from	IN	O
human	JJ	O
placenta	NN	O
)	)	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
10	CD	O
μg/100	JJ	O
μl/cm2	NN	O
.	.	O
2	CD	O
.	.	O
Fibronectin	NNP	O
(	(	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma	NN	O
)	)	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	O
μg/100	JJ	O
μl/cm2	NN	O
.	.	O
3	CD	O
.	.	O
Vitronectin	NNP	O
(	(	O
isolated	VBN	O
from	IN	O
human	JJ	O
plasma	NN	O
)	)	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.2	CD	O
μg/100	JJ	O
μl/cm2	NN	O
.	.	O
4	CD	O
.	.	O
Laminin	NNP	O
(	(	O
isolated	VBN	O
from	IN	O
human	JJ	O
placenta	NN	O
)	)	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
μg/100	NNP	O
μl/cm2	NNP	O
.	.	O
To	TO	O
assemble	VB	O
this	DT	O
matrix	NN	O
,	,	O
the	DT	O
collagen	NN	O
is	VBZ	O
denatured	VBN	O
with	IN	O
6M	CD	O
GuHCl	NNP	O
(	(	O
guanidine	JJ	O
HCl	NNP	O
)	)	O
,	,	O
filtered	VBN	O
through	IN	O
a	DT	O
0.45	CD	O
micron	NN	O
filter	NN	O
and	CC	O
frozen	NN	O
in	IN	O
aliquots	NNS	O
.	.	O
Upon	IN	O
thaw	NN	O
,	,	O
denatured	VBD	O
collagen	NN	O
was	VBD	O
diluted	VBN	O
into	IN	O
Ca-	NNP	O
and	CC	O
Mg-free	NNP	O
phosphate	NN	O
buffered	VBD	O
saline	NN	O
(	(	O
PBS	NNP	O
)	)	O
,	,	O
to	TO	O
achieve	VB	O
the	DT	O
appropriate	JJ	O
final	JJ	O
concentration	NN	O
and	CC	O
was	VBD	O
then	RB	O
plated	VBN	O
.	.	O
The	DT	O
coated	JJ	O
plates	NNS	O
were	VBD	O
allowed	VBN	O
to	TO	O
incubate	VB	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	O
hour	NN	O
before	IN	O
the	DT	O
additional	JJ	O
matrix	NN	O
components	NNS	O
were	VBD	O
plated	VBN	O
.	.	O
Following	VBG	O
this	DT	O
initial	JJ	O
incubation	NN	O
,	,	O
additional	JJ	O
matrix	NN	O
components	NNS	O
(	(	O
fibronectin	NN	O
,	,	O
vitronectin	NN	O
and	CC	O
laminin	NN	O
)	)	O
were	VBD	O
diluted	VBN	O
into	IN	O
a	DT	O
Ca-	JJ	O
and	CC	O
Mg-free	JJ	O
PBS	NNP	O
to	TO	O
achieve	VB	O
the	DT	O
appropriate	JJ	O
final	JJ	O
concentration	NN	O
and	CC	O
plated	VBN	O
.	.	O
The	DT	O
coated	JJ	O
plates	NNS	O
were	VBD	O
allowed	VBN	O
to	TO	O
incubate	VB	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	O
hour	NN	O
before	IN	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
ES	NNP	O
and	CC	O
iPS	VB	O
cells	NNS	O
)	)	O
were	VBD	O
plated	VBN	O
.	.	O
The	DT	O
combination	NN	O
of	IN	O
four	CD	O
human	JJ	O
proteins	NNS	O
was	VBD	O
found	VBN	O
to	TO	O
support	VB	O
robust	JJ	O
,	,	O
long-term	JJ	O
proliferation	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
TeSR1	NNP	O
.	.	O
Using	VBG	O
the	DT	O
new	JJ	O
matrix	NN	O
material	NN	O
,	,	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
of	IN	O
previously	RB	O
existing	VBG	O
lines	NNS	O
have	VBP	O
been	VBN	O
cultured	VBN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
10	CD	O
passages	NNS	O
while	IN	O
remaining	VBG	O
undifferentiated	JJ	O
and	CC	O
proliferating	NN	O
.	.	O
Specifically	RB	O
,	,	O
cell	NN	O
lines	NNS	O
H1	NNP	O
and	CC	O
H9	NNP	O
,	,	O
cultured	VBD	O
in	IN	O
TeSR1	NNP	O
on	IN	O
the	DT	O
human	JJ	O
matrix	NN	O
for	IN	O
11	CD	O
and	CC	O
16	CD	O
passages	NNS	O
,	,	O
respectively	RB	O
,	,	O
continued	VBD	O
to	TO	O
express	VB	O
markers	NNS	O
characteristic	JJ	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
)	)	O
.	.	O
Human	NNP	O
ES	NNP	O
cells	NNS	O
cultured	VBD	O
for	IN	O
5	CD	O
passages	NNS	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
continued	VBD	O
to	TO	O
show	VB	O
morphology	JJ	O
characteristics	NNS	O
of	IN	O
ES	NNP	O
cells	NNS	O
,	,	O
and	CC	O
to	TO	O
express	VB	O
markers	NNS	O
characteristic	JJ	O
of	IN	O
ES	NNP	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
)	)	O
.	.	O
Analyses	NNS	O
for	IN	O
internal	JJ	O
(	(	O
Oct-4	NNP	O
)	)	O
or	CC	O
cell	NN	O
surface	NN	O
(	(	O
SSEA4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
,	,	O
Tra	NNP	O
1-81	CD	O
)	)	O
markers	NNS	O
after	IN	O
11	CD	O
passages	NNS	O
of	IN	O
culture	NN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
components	NNS	O
(	(	O
FIG	NNP	O
.	.	O
11	CD	O
d-g	NN	O
)	)	O
were	VBD	O
all	DT	O
greater	JJR	O
than	IN	O
90	CD	O
%	NN	O
percent	NN	O
positive	JJ	O
.	.	O
To	TO	O
test	VB	O
the	DT	O
strict	JJ	O
necessity	NN	O
for	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
humanized	JJ	O
matrix	NN	O
,	,	O
variations	NNS	O
on	IN	O
the	DT	O
matrix	NN	O
were	VBD	O
formulated	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
components	NNS	O
omitted	VBN	O
.	.	O
The	DT	O
data	NN	O
from	IN	O
that	DT	O
experiment	NN	O
is	VBZ	O
presented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
.	.	O
Note	NN	O
that	IN	O
CFV	NNP	O
,	,	O
CVL	NNP	O
and	CC	O
CFL	NNP	O
matrices	NNS	O
do	VBP	O
work	VB	O
well	RB	O
and	CC	O
maintain	VB	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
ES	NNP	O
and	CC	O
iPS	JJ	O
cells	NNS	O
,	,	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
.	.	O
Also	RB	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
it	PRP	O
is	VBZ	O
envisioned	VBN	O
that	IN	O
CV	NNP	O
,	,	O
CF	NNP	O
,	,	O
and	CC	O
CL	NNP	O
could	MD	O
also	RB	O
maintain	VB	O
cell	NN	O
growth	NN	O
and	CC	O
prevent	NN	O
differentiation	NN	O
.	.	O
Morphological	JJ	O
assessment	NN	O
and	CC	O
visual	JJ	O
observations	NNS	O
of	IN	O
attachment	JJ	O
suggest	NN	O
that	IN	O
using	VBG	O
only	RB	O
two	CD	O
components	NNS	O
of	IN	O
the	DT	O
humanized	JJ	O
matrix	NN	O
one	CD	O
can	MD	O
achieve	VB	O
attachment	NN	O
,	,	O
although	IN	O
at	IN	O
a	DT	O
lower	JJR	O
rate	NN	O
than	IN	O
with	IN	O
three	CD	O
or	CC	O
four	CD	O
components	NNS	O
.	.	O
The	DT	O
CVFL	NNP	O
matrix	NN	O
is	VBZ	O
simply	RB	O
more	RBR	O
conducive	JJ	O
to	TO	O
cell	VB	O
culture	NN	O
growth	NN	O
.	.	O
Generally	RB	O
,	,	O
CVFL	NNP	O
matrices	NNS	O
provide	VBP	O
greater	JJR	O
attachment	NN	O
than	IN	O
CFV	NNP	O
,	,	O
CVL	NNP	O
,	,	O
or	CC	O
CFL	NNP	O
matrices	NNS	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
provide	VBP	O
greater	JJR	O
attachment	NN	O
than	IN	O
CF	NNP	O
,	,	O
CL	NNP	O
,	,	O
or	CC	O
CV	NNP	O
matrices	NNS	O
(	(	O
these	DT	O
observations	NNS	O
represent	VBP	O
three	CD	O
replicates	NNS	O
;	:	O
data	NNS	O
not	RB	O
shown	VBN	O
)	)	O
.	.	O
TeSR1	NNP	O
as	IN	O
defined	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
includes	VBZ	O
BME	NNP	O
(	(	O
i.e.	FW	O
,	,	O
2-mercaptothanol	JJ	O
)	)	O
.	.	O
Generally	RB	O
,	,	O
it	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
BME	NNP	O
reduces	NNS	O
disulfide	JJ	O
bonds	NNS	O
and	CC	O
acts	NNS	O
as	IN	O
an	DT	O
antioxidant	NN	O
by	IN	O
scavenging	VBG	O
hydroxyl	JJ	O
radicals	NNS	O
.	.	O
When	WRB	O
BME	NNP	O
is	VBZ	O
added	VBN	O
to	TO	O
cell	VB	O
culture	NN	O
medium	NN	O
it	PRP	O
is	VBZ	O
generally	RB	O
believed	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
oxidative	JJ	O
stress	NN	O
on	IN	O
cells	NNS	O
in	IN	O
culture	NN	O
.	.	O
To	TO	O
test	VB	O
the	DT	O
strict	JJ	O
necessity	NN	O
for	IN	O
BME	NNP	O
in	IN	O
TeSR1	NNP	O
,	,	O
we	PRP	O
tested	VBD	O
5	CD	O
doses	NNS	O
of	IN	O
BME	NNP	O
in	IN	O
modified	JJ	O
TeSR1	NN	O
:	:	O
0	CD	O
,	,	O
1.75	CD	O
,	,	O
3.5	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
μL	NN	O
BME/500	NNP	O
mL	NN	O
of	IN	O
total	JJ	O
media	NNS	O
(	(	O
FIG	NNP	O
.	.	O
15	CD	O
)	)	O
.	.	O
Based	VBN	O
on	IN	O
cell	NN	O
counts	NNS	O
and	CC	O
pluripotency	NN	O
,	,	O
0	CD	O
and	CC	O
1.75	CD	O
μL	NN	O
BME/500	NNP	O
mL	NN	O
of	IN	O
total	JJ	O
media	NNS	O
yielded	VBD	O
large	JJ	O
increases	NNS	O
in	IN	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
15	CD	O
b	NN	O
)	)	O
.	.	O
These	DT	O
data	NNS	O
confirm	VBP	O
that	IN	O
it	PRP	O
is	VBZ	O
feasible	JJ	O
and	CC	O
in	IN	O
some	DT	O
instances	NNS	O
advantageous	JJ	O
to	TO	O
culture	NN	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
in	IN	O
TeSR1	NNP	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
BME	NNP	O
.	.	O
To	TO	O
confirm	VB	O
that	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
supports	VBZ	O
culture	NN	O
of	IN	O
non-embryonic	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
in	IN	O
an	DT	O
undifferentiated	JJ	O
state	NN	O
,	,	O
two	CD	O
iPS	NN	O
cells	NNS	O
lines	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
modified	JJ	O
TeSR1	NNP	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
)	)	O
.	.	O
The	DT	O
iPS	NN	O
cell	NN	O
line	NN	O
IMR90	NNP	O
(	(	O
Yu	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
2007	CD	I
;	:	O
and	CC	O
provided	VBN	O
by	IN	O
WISC	NNP	O
Bank	NNP	O
)	)	O
was	VBD	O
cultured	VBN	O
for	IN	O
at	IN	O
least	JJS	O
10	CD	O
passages	NNS	O
in	IN	O
mTeSR1	NN	O
.	.	O
Through	IN	O
10	CD	O
passages	NNS	O
IMR90	NNP	O
maintained	VBD	O
greater	JJR	O
than	IN	O
95	CD	O
%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
16	CD	O
a	DT	O
)	)	O
.	.	O
The	DT	O
vector-free	JJ	O
iPS	NN	O
cell	NN	O
line	NN	O
iPS-DF-19-9	NN	O
(	(	O
Yu	NNP	B
et	RB	I
al.	RB	I
,	,	I
2009	CD	I
Science	NN	I
;	:	O
also	RB	O
provided	VBN	O
by	IN	O
WISC	NNP	O
Bank	NNP	O
)	)	O
was	VBD	O
cultured	VBN	O
for	IN	O
at	IN	O
least	JJS	O
16	CD	O
passages	NNS	O
in	IN	O
mTeSR1	NN	O
.	.	O
iPS-DF-19-9	NN	O
maintained	VBD	O
more	JJR	O
than	IN	O
98	CD	O
%	NN	O
Oct-4	NNP	O
positive	JJ	O
cells	NNS	O
,	,	O
through	IN	O
16	CD	O
passages	NNS	O
(	(	O
FIG	NNP	O
.	.	O
16B	CD	O
)	)	O
.	.	O
Recently	RB	O
,	,	O
other	JJ	O
research	NN	O
groups	NNS	O
have	VBP	O
also	RB	O
confirmed	VBN	O
that	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
supports	NNS	O
cell	NN	O
culture	NN	O
,	,	O
maintenance	NN	O
and	CC	O
derivation	NN	O
of	IN	O
iPS	NN	O
cells	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
Sun	NNP	O
N	NNP	O
,	,	O
et	RB	O
al	NN	O
.	.	O
reports	NNS	O
the	DT	O
feeder-free	JJ	O
derivation	NN	O
of	IN	O
induced	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
from	IN	O
adult	NN	O
human	JJ	O
adipose	JJ	O
stem	NN	O
cells	NNS	O
with	IN	O
mTeSR1	JJ	O
hES	NN	O
growth	NN	O
medium	NN	O
available	JJ	O
through	IN	O
StemCell	NNP	O
Technologies	NNPS	O
located	VBN	O
in	IN	O
Vancouver	NNP	O
,	,	O
BC	NNP	O
,	,	O
Canada	NNP	O
.	.	O
(	(	O
Sun	NNP	B
N	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
PNAS	$	I
106	CD	I
(	(	I
37	CD	I
)	)	I
,	,	I
15720-15725	JJ	I
(	(	I
2009	CD	I
)	)	I
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
)	)	O
.	.	O
Likewise	RB	O
,	,	O
Chan	NNP	O
E	NNP	O
M	NNP	O
,	,	O
et	RB	O
al	NN	O
.	.	O
have	VBP	O
used	VBN	O
mTeSR1	NN	O
medium	NN	O
to	TO	O
derive	VB	O
fully	RB	O
reprogrammed	VBN	O
iPS	JJ	O
cells	NNS	O
on	IN	O
Matrigel™	NNP	O
and	CC	O
shown	VBN	O
that	IN	O
live	JJ	O
cell	NN	O
imaging	VBG	O
can	MD	O
distinguish	VB	O
bona	JJ	O
fide	JJ	O
human	JJ	O
iPS	NN	O
cells	NNS	O
from	IN	O
partially	RB	O
reprogrammed	VBN	O
cells	NNS	O
(	(	O
Chan	NNP	B
et	RB	I
al	RB	I
.	.	I
Nat	NNP	I
.	.	I
Biotech	NN	I
2009	CD	I
Nov.	NNP	I
27	CD	I
(	(	I
11	CD	I
)	)	I
:1033-7	NN	I
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
)	)	O
.	.	O
Collectively	RB	O
,	,	O
these	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
TeSR1	NNP	O
defined	VBD	O
medium	NN	O
can	MD	O
support	VB	O
cell	NN	O
culture	NN	O
maintenance	NN	O
and	CC	O
derivation	NN	O
of	IN	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
derived	VBN	O
from	IN	O
somatic	JJ	O
cells	NNS	O
.	.	O
As	IN	O
described	VBN	O
above	IN	O
,	,	O
mTeSR1	NN	O
and	CC	O
the	DT	O
original	JJ	O
TeSR1	NNP	O
have	VBP	O
the	DT	O
same	JJ	O
function	NN	O
and	CC	O
are	VBP	O
chemically	RB	O
similar	JJ	O
.	.	O
The	DT	O
main	JJ	O
difference	NN	O
is	VBZ	O
that	IN	O
TeSR1	NNP	O
medium	NN	O
contains	VBZ	O
HSA	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
very	RB	O
expensive	JJ	O
,	,	O
and	CC	O
the	DT	O
mTeSR	NN	O
medium	NN	O
contains	VBZ	O
bovine	JJ	O
serum	NN	O
albumin	NN	O
(	(	O
BSA	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
more	RBR	O
commercially	RB	O
economical	JJ	O
.	.	O
Because	IN	O
HSA	NNP	O
is	VBZ	O
expensive	JJ	O
to	TO	O
obtain	VB	O
,	,	O
the	DT	O
inventors	NNS	O
routinely	RB	O
use	VBP	O
BSA	NNP	O
as	IN	O
a	DT	O
less	RBR	O
costly	JJ	O
substitute	NN	O
.	.	O
Although	IN	O
the	DT	O
species	NNS	O
source	NN	O
of	IN	O
the	DT	O
albumin	NN	O
is	VBZ	O
different	JJ	O
,	,	O
BSA	NNP	O
in	IN	O
the	DT	O
TeSR	NNP	O
medium	NN	O
(	(	O
mTeSR1	NN	O
)	)	O
functions	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
its	PRP$	O
humanized	JJ	O
counterpart	NN	O
,	,	O
TeSR1	NNP	O
medium	NN	O
,	,	O
which	WDT	O
contains	VBZ	O
HSA	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
note	VB	O
that	IN	O
this	DT	O
humanized	JJ	O
version	NN	O
of	IN	O
TeSR	NNP	O
has	VBZ	O
been	VBN	O
renamed	VBN	O
and	CC	O
is	VBZ	O
currently	RB	O
marketed	VBN	O
as	IN	O
TeSR2	NNP	O
by	IN	O
Stem	NNP	O
Cell	NNP	O
Technologies	NNPS	O
(	(	O
Vancouver	NNP	O
,	,	O
BC	NNP	O
,	,	O
Canada	NNP	O
)	)	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
prior	JJ	O
ES	NNP	O
cell	NN	O
cultures	NNS	O
are	VBP	O
less	JJR	O
than	IN	O
optimal	JJ	O
because	IN	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
Neu5Gc	NNP	O
,	,	O
a	DT	O
sialic	JJ	O
acid	NN	O
not	RB	O
made	VBN	O
by	IN	O
humans	NNS	O
,	,	O
contaminating	VBG	O
human	JJ	O
ES	NNP	O
cells	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
to	TO	O
determine	VB	O
whether	IN	O
Neu5Gc	NNP	O
could	MD	O
be	VB	O
eliminated	VBN	O
from	IN	O
existing	VBG	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
,	,	O
H9	NNP	O
cells	NNS	O
were	VBD	O
grown	VBN	O
under	IN	O
three	CD	O
different	JJ	O
conditions	NNS	O
,	,	O
1	CD	O
)	)	O
conditioned	VBD	O
medium	NN	O
on	IN	O
Matrigel	NNP	O
,	,	O
42	CD	O
passages	NNS	O
2	CD	O
)	)	O
TeSR1	NN	O
on	IN	O
Matrigel	NNP	O
,	,	O
16	CD	O
passages	NNS	O
and	CC	O
3	CD	O
)	)	O
TeSR1	NN	O
on	IN	O
human	JJ	O
matrix	NN	O
,	,	O
5	CD	O
passages	NNS	O
.	.	O
Approximately	RB	O
2×107	CD	O
cells	NNS	O
from	IN	O
each	DT	O
condition	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
purified	VBN	O
for	IN	O
analysis	NN	O
employing	VBG	O
methods	NNS	O
similar	JJ	O
to	TO	O
those	DT	O
described	VBN	O
previously	RB	O
(	(	O
see	VB	O
Bardor	NNP	B
,	,	I
M.	NNP	I
et	CC	I
al	NN	I
.	.	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
280	CD	I
,	,	I
4228-4237	CD	I
;	:	I
2005	CD	I
)	)	O
.	.	O
The	DT	O
purified	JJ	O
sialic	JJ	O
acids	NNS	O
were	VBD	O
derivatized	VBN	O
with	IN	O
DMB	NNP	O
(	(	O
1,2-diamino-4,5-methylenedioxybenzene	JJ	O
dihydrochloride	NN	O
)	)	O
(	(	O
Dojindo	NNP	O
)	)	O
to	TO	O
take	VB	O
advantage	NN	O
of	IN	O
previously	RB	O
described	VBN	O
detection	NN	O
methods	NNS	O
via	IN	O
liquid	JJ	O
chromatography-mass	NN	O
spectrometry	NN	O
(	(	O
LC-MS	NNP	O
)	)	O
.	.	O
The	DT	O
inventors	NNS	O
employed	VBD	O
a	DT	O
Surveyor	NNP	O
HPLC	NNP	O
in-line	NN	O
with	IN	O
a	DT	O
LCQ	NNP	O
DECA	NNP	O
XP	NNP	O
Plus	NNP	O
ion	NN	O
trap	NN	O
mass	NN	O
spectrometer	NN	O
(	(	O
ThermoElectron	NNP	O
)	)	O
.	.	O
The	DT	O
Genesis	NNP	O
C18	NNP	O
,	,	O
120	CD	O
angstrom	NN	O
,	,	O
4	CD	O
micron	NN	O
particle	NN	O
size	NN	O
(	(	O
Grace	NNP	O
Vydac	NNP	O
)	)	O
column	NN	O
was	VBD	O
packed	VBN	O
in-house	NN	O
(	(	O
250	CD	O
micron	NN	O
by	IN	O
100	CD	O
mm	NN	O
)	)	O
.	.	O
Sample	JJ	O
elution	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
ramping	VBG	O
a	DT	O
linear	JJ	O
gradient	NN	O
from	IN	O
14	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
organic	JJ	O
(	(	O
acetonitrile	IN	O
:	:	O
methanol	NN	O
)	)	O
in	IN	O
0.1	CD	O
%	NN	O
aqueous	JJ	O
formic	JJ	O
acid	NN	O
over	IN	O
10	CD	O
minutes	NNS	O
at	IN	O
a	DT	O
flow	JJ	O
rate	NN	O
of	IN	O
1	CD	O
μl/min	NNS	O
(	(	O
all	DT	O
solvents	NNS	O
:	:	O
Burdick	NNP	O
&	CC	O
Jackson	NNP	O
:	:	O
High	NNP	O
Purity	NNP	O
)	)	O
.	.	O
Electrospray	NNP	O
voltage	NN	O
of	IN	O
3300V	CD	O
,	,	O
175°	CD	O
C.	NNP	O
capillary	JJ	O
temperature	NN	O
and	CC	O
a	DT	O
nitrogen	JJ	O
sheath	NN	O
gas	NN	O
of	IN	O
15	CD	O
psi	NNS	O
were	VBD	O
employed	VBN	O
.	.	O
Data	NNP	O
acquisition	NN	O
was	VBD	O
set	VBN	O
for	IN	O
a	DT	O
full	JJ	O
scan	JJ	O
MS	NNP	O
followed	VBN	O
by	IN	O
two	CD	O
sequential	JJ	O
MS/MS	NNP	O
acquisitions	NNS	O
for	IN	O
the	DT	O
parent	NN	O
masses	NNS	O
of	IN	O
the	DT	O
Neu5Ac	NNP	O
and	CC	O
Neu5Gc	NNP	O
(	(	O
426	CD	O
and	CC	O
442	CD	O
m/z	NN	O
)	)	O
derivatized	VBN	O
products	NNS	O
.	.	O
Reconstructed	VBN	O
ion	NN	O
chromatograms	NNS	O
were	VBD	O
plotted	VBN	O
for	IN	O
the	DT	O
principle	NN	O
MS/MS	NNP	O
daughter	NN	O
ions	NNS	O
for	IN	O
Neu5Ac	NNP	O
and	CC	O
Neu5Gc	NNP	O
at	IN	O
408	CD	O
m/z	NN	O
and	CC	O
424	CD	O
m/z	NN	O
respectively	RB	O
.	.	O
Conditions	NNS	O
for	IN	O
derivatization	NN	O
and	CC	O
LC-MS	JJ	O
analysis	NN	O
were	VBD	O
established	VBN	O
using	VBG	O
commercially	RB	O
purchased	VBN	O
standards	NNS	O
of	IN	O
Neu5Ac	NNP	O
and	CC	O
Neu5Gc	NNP	O
(	(	O
Sigma-Aldrich	NNP	O
)	)	O
.	.	O
The	DT	O
inventors	NNS	O
found	VBD	O
that	IN	O
Neu5Gc	NNP	O
was	VBD	O
present	JJ	O
on	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
fibroblast	NN	O
conditioned	JJ	O
medium	NN	O
.	.	O
A	DT	O
reduced	VBN	O
but	CC	O
detectable	JJ	O
amount	NN	O
of	IN	O
Neu5Gc	NNP	O
was	VBD	O
found	VBN	O
on	IN	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
Matrigel	NNP	O
.	.	O
However	RB	O
,	,	O
no	DT	O
Neu5Gc	NNP	O
was	VBD	O
detected	VBN	O
on	IN	O
ES	NNP	O
cells	NNS	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
using	VBG	O
the	DT	O
four	CD	O
human	JJ	O
matrix	NN	O
components	NNS	O
.	.	O
These	DT	O
data	NNS	O
are	VBP	O
illustrated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
12	CD	O
.	.	O
Thus	RB	O
,	,	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
cultured	VBN	O
on	IN	O
TeSR1	NNP	O
and	CC	O
on	IN	O
a	DT	O
matrix	NN	O
of	IN	O
human	JJ	O
proteins	NNS	O
do	VBP	O
not	RB	O
exhibit	VB	O
the	DT	O
non-human	JJ	O
sialic	JJ	O
acid	NN	O
residues	NNS	O
found	VBN	O
on	IN	O
cells	NNS	O
cultured	VBN	O
on	IN	O
murine	NN	O
feeder	NN	O
cells	NNS	O
.	.	O
This	DT	O
medium	NN	O
has	VBZ	O
also	RB	O
proven	VBN	O
capable	JJ	O
of	IN	O
supporting	VBG	O
the	DT	O
initiation	NN	O
of	IN	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
The	DT	O
derivation	NN	O
process	NN	O
for	IN	O
new	JJ	O
lines	NNS	O
can	MD	O
be	VB	O
a	DT	O
difficult	JJ	O
test	NN	O
for	IN	O
medium	NN	O
formulations	NNS	O
,	,	O
but	CC	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
defined	JJ	O
medium	NN	O
makes	VBZ	O
it	PRP	O
possible	JJ	O
to	TO	O
create	VB	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
which	WDT	O
have	VBP	O
not	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
non-human	JJ	O
animal	JJ	O
proteins	NNS	O
or	CC	O
matrices	NNS	O
,	,	O
and	CC	O
have	VBP	O
never	RB	O
been	VBN	O
exposed	VBN	O
to	TO	O
feeder	VB	O
cells	NNS	O
or	CC	O
medium	NN	O
in	IN	O
which	WDT	O
feeder	NN	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
.	.	O
This	DT	O
is	VBZ	O
believed	VBN	O
to	TO	O
be	VB	O
a	DT	O
novel	JJ	O
and	CC	O
unexpected	JJ	O
achievement	NN	O
.	.	O
This	DT	O
work	NN	O
was	VBD	O
undertaken	VBN	O
only	RB	O
after	IN	O
obtaining	VBG	O
institutional	JJ	O
review	NN	O
board	NN	O
approval	NN	O
and	CC	O
informed	JJ	O
consent	NN	O
from	IN	O
donors	NNS	O
(	(	O
HSC	NNP	O
Protocol	NNP	O
#	#	O
2000-434	JJ	O
)	)	O
.	.	O
Frozen	NNP	O
human	JJ	O
pre-embryos	NN	O
that	WDT	O
were	VBD	O
fertilized	VBN	O
for	IN	O
fertility	NN	O
treatment	NN	O
but	CC	O
were	VBD	O
in	IN	O
excess	NN	O
of	IN	O
clinic	JJ	O
need	NN	O
were	VBD	O
thawed	VBN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
deriving	VBG	O
new	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
.	.	O
Using	VBG	O
commercially	RB	O
available	JJ	O
sequential	JJ	O
embryo	NN	O
culture	NN	O
media	NNS	O
(	(	O
Vitrolife-GIII	NNP	O
Series	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
5	CD	O
%	NN	O
Serum	NNP	O
Protein	NNP	O
Substitute	NNP	O
(	(	O
SPS	NNP	O
:	:	O
Cooper	NNP	O
Surgical	NNP	O
)	)	O
,	,	O
the	DT	O
frozen/thawed	VBN	O
embryos	NN	O
were	VBD	O
cultured	VBN	O
for	IN	O
seven	CD	O
days	NNS	O
in	IN	O
10	CD	O
μL	JJ	O
drops	NNS	O
under	IN	O
oil	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
and	CC	O
5	CD	O
%	NN	O
O2/10	NNP	O
%	NN	O
CO2/85	NNP	O
%	NN	O
N2	NNP	O
.	.	O
After	IN	O
removal	NN	O
of	IN	O
the	DT	O
zona	NN	O
pellucida	NN	O
with	IN	O
pronase	NN	O
,	,	O
the	DT	O
inner	NN	O
cell	NN	O
mass	NN	O
(	(	O
ICM	NNP	O
)	)	O
of	IN	O
five	CD	O
human	JJ	O
blastocysts	NNS	O
were	VBD	O
isolated	VBN	O
by	IN	O
immunosurgery	NN	O
(	(	O
Solter	NNP	B
and	CC	I
Knowles	NNP	I
,	,	I
1975	CD	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
72:5099-5102	NNP	I
)	)	O
or	CC	O
as	IN	O
cultured	JJ	O
whole	JJ	O
mounts	NNS	O
(	(	O
Evans	NNPS	B
and	CC	I
Kaufman	NNP	I
,	,	I
1981	CD	I
,	,	I
Nature	NNP	I
,	,	I
292154-156	JJ	I
)	)	O
and	CC	O
plated	VBN	O
in	IN	O
4-well	JJ	O
culture	NN	O
plates	NNS	O
(	(	O
Nunc	NNP	O
)	)	O
onto	IN	O
the	DT	O
defined	JJ	O
medium	NN	O
TeSR1	NNP	O
with	IN	O
the	DT	O
defined	JJ	O
humanized	JJ	O
matrix	NN	O
,	,	O
CVFL	NNP	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Following	VBG	O
an	DT	O
initial	JJ	O
48	CD	O
hours	NNS	O
of	IN	O
culture	NN	O
,	,	O
the	DT	O
culture	NN	O
medium	NN	O
(	(	O
TeSR1	NNP	O
)	)	O
was	VBD	O
replaced	VBN	O
on	IN	O
a	DT	O
daily	JJ	O
basis	NN	O
.	.	O
After	IN	O
14	CD	O
to	TO	O
21	CD	O
days	NNS	O
,	,	O
clumps	NNS	O
of	IN	O
cells	NNS	O
were	VBD	O
mechanically	RB	O
isolated	JJ	O
and	CC	O
replated	JJ	O
onto	IN	O
fresh	JJ	O
human	JJ	O
matrix	NN	O
.	.	O
Mechanical	JJ	O
isolation	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
the	DT	O
subsequent	JJ	O
2	CD	O
to	TO	O
3	CD	O
passages	NNS	O
after	IN	O
which	WDT	O
colonies	NNS	O
were	VBD	O
passaged	VBN	O
using	VBG	O
0.5	CD	O
mg/ml	JJ	O
dispase	NN	O
(	(	O
Invitrogen	NNP	O
)	)	O
.	.	O
The	DT	O
new	JJ	O
colonies	NNS	O
were	VBD	O
confirmed	VBN	O
to	TO	O
be	VB	O
new	JJ	O
lines	NNS	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
using	VBG	O
standard	JJ	O
cell	NN	O
line	NN	O
characterization	NN	O
techniques	NNS	O
.	.	O
Using	VBG	O
TeSR1	NNP	O
medium	NN	O
on	IN	O
the	DT	O
four	CD	O
human	JJ	O
matrix	NN	O
components	NNS	O
,	,	O
CVFL	NNP	O
,	,	O
two	CD	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
(	(	O
WA15	NNP	O
and	CC	O
WA16	NNP	O
;	:	O
FIG	NNP	O
.	.	O
13	CD	O
)	)	O
were	VBD	O
derived	VBN	O
from	IN	O
5	CD	O
cultured	JJ	O
blastocysts	NNS	O
.	.	O
Both	DT	O
human	JJ	O
ES	NNP	O
cell	NN	O
lines	NNS	O
have	VBP	O
now	RB	O
been	VBN	O
continuously	RB	O
in	IN	O
culture	NN	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	O
months	NNS	O
.	.	O
Analysis	NN	O
of	IN	O
these	DT	O
lines	NNS	O
by	IN	O
fluorescence-activated	JJ	O
cell	NN	O
sorting	VBG	O
(	(	O
FACS	NNP	O
)	)	O
and	CC	O
RT-PCR	NNP	O
demonstrated	VBD	O
that	IN	O
they	PRP	O
express	VBP	O
markers	NNS	O
characteristic	JJ	O
of	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
13	CD	O
)	)	O
,	,	O
and	CC	O
both	DT	O
cell	NN	O
lines	NNS	O
formed	VBN	O
teratomas	NN	O
when	WRB	O
injected	VBN	O
into	IN	O
severe	JJ	O
combined	VBN	O
immunodeficient-beige	JJ	O
mice	NN	O
.	.	O
FACS	NNP	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
first	JJ	O
removing	VBG	O
the	DT	O
cells	NNS	O
from	IN	O
the	DT	O
culture	NN	O
dish	NN	O
with	IN	O
Trypsin/EDTA	NNP	O
(	(	O
Invitrogen	NNP	O
)	)	O
containing	VBG	O
2	CD	O
%	NN	O
chick	NN	O
serum	NN	O
(	(	O
ICN	NNP	O
)	)	O
for	IN	O
10	CD	O
minutes	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
and	CC	O
resuspended	VBD	O
in	IN	O
1	CD	O
ml	NNS	O
fluorescence	RB	O
activated	VBD	O
cell	NN	O
sorting	NN	O
(	(	O
FACS	NNP	O
)	)	O
buffer	VBP	O
[	JJ	O
PBS	NNP	O
−/−	NNP	O
(	(	O
Invitrogen	NNP	O
)	)	O
containing	VBG	O
0.1	CD	O
%	NN	O
sodium	NN	O
azide	NN	O
(	(	O
Sigma	NNP	O
)	)	O
and	CC	O
2	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Gibco	NNP	O
)	)	O
]	NN	O
.	.	O
Cells	NNS	O
to	TO	O
be	VB	O
probed	VBN	O
for	IN	O
the	DT	O
internal	JJ	O
marker	NN	O
Oct-4	NNP	O
were	VBD	O
fixed	VBN	O
with	IN	O
0.1	CD	O
%	NN	O
paraformaldehyde	NN	O
(	(	O
Electron	NNP	O
Microscopy	NNP	O
Sciences	NNPS	O
)	)	O
for	IN	O
10	CD	O
min	NN	O
.	.	O
at	IN	O
37°	CD	O
C.	NNP	O
then	RB	O
permeabilized	VBD	O
with	IN	O
90	CD	O
%	NN	O
methanol	NN	O
(	(	O
Fisher	NNP	O
Scientific	NNP	O
)	)	O
for	IN	O
30	CD	O
min	NN	O
on	IN	O
ice	NN	O
.	.	O
1-5×105	JJ	O
fixed	VBN	O
(	(	O
Oct-4	NNP	O
)	)	O
or	CC	O
live	JJ	O
(	(	O
SSEA-4	NNP	O
,	,	O
Tra	NNP	O
1-60	CD	O
or	CC	O
Tra	NNP	O
1-81	CD	O
)	)	O
cells	NNS	O
were	VBD	O
then	RB	O
probed	VBN	O
for	IN	O
30	CD	O
min	NN	O
at	IN	O
room	NN	O
temperature	NN	O
with	IN	O
a	DT	O
1:100	CD	O
dilution	NN	O
of	IN	O
the	DT	O
specific	JJ	O
monoclonal	JJ	O
antibody	NN	O
or	CC	O
an	DT	O
appropriate	JJ	O
isotype	NN	O
control	NN	O
antibody	NN	O
(	(	O
Santa	NNP	O
Cruz	NNP	O
Biotechnology	NNP	O
,	,	O
Inc.	NNP	O
)	)	O
in	IN	O
FACS	NNP	O
buffer	NN	O
(	(	O
+0.1	CD	O
%	NN	O
Triton-X100	NNP	O
for	IN	O
fixed	JJ	O
cells	NNS	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
then	RB	O
washed	VBN	O
and	CC	O
probed	VBN	O
in	IN	O
FACS	NNP	O
buffer	NN	O
(	(	O
+0.5	CD	O
%	NN	O
Triton-X100	NNP	O
for	IN	O
fixed	JJ	O
cells	NNS	O
)	)	O
with	IN	O
1:1000	CD	O
dilution	NN	O
of	IN	O
an	DT	O
Alexaflour	NNP	O
anti-mouse	NN	O
secondary	JJ	O
antibody	NN	O
(	(	O
Invitrogen	NNP	O
)	)	O
for	IN	O
30	CD	O
min	NN	O
in	IN	O
the	DT	O
dark	NN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
Cells	NNS	O
with	IN	O
the	DT	O
EGFP-Oct-4	JJ	O
knock-in	JJ	O
construct	NN	O
were	VBD	O
collected	VBN	O
and	CC	O
analyzed	VBN	O
directly	RB	O
.	.	O
Cell	NNP	O
were	VBD	O
washed	VBN	O
in	IN	O
FACS	NNP	O
Buffer	NNP	O
,	,	O
and	CC	O
sorted	VBD	O
using	VBG	O
a	DT	O
FACSCalibur	NNP	O
flow	NN	O
cytometer	NN	O
(	(	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
.	.	O
Acquisition	NNP	O
was	VBD	O
set	VBN	O
for	IN	O
10,000	CD	O
events	NNS	O
per	IN	O
sample	NN	O
.	.	O
Dead	JJ	O
cells	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
analysis	NN	O
by	IN	O
staining	VBG	O
with	IN	O
propidium	NN	O
iodide	NN	O
(	(	O
Invitrogen	NNP	O
)	)	O
.	.	O
Data	NNS	O
were	VBD	O
analyzed	VBN	O
with	IN	O
CellQuest	NNP	O
3.0	CD	O
software	NN	O
(	(	O
Becton	NNP	O
Dickinson	NNP	O
)	)	O
.	.	O
All	DT	O
treatments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
duplicate	NN	O
.	.	O
Multiple	JJ	O
replicates	NNS	O
were	VBD	O
performed	VBN	O
for	IN	O
each	DT	O
experiment	NN	O
.	.	O
RT-PCR	NNP	O
was	VBD	O
performed	VBN	O
with	IN	O
previously	RB	O
described	VBN	O
gene-specific	JJ	O
primers	NNS	O
on	IN	O
100	CD	O
ng	NN	O
of	IN	O
total	JJ	O
RNA	NNP	O
per	IN	O
reaction	NN	O
using	VBG	O
an	DT	O
OneStep	NNP	O
RT-PCR	JJ	O
Kit	NNP	O
(	(	O
Qiagen	NNP	O
)	)	O
following	VBG	O
manufacturer	NN	O
's	POS	O
recommendations	NNS	O
.	.	O
RNA	JJ	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
UV	NNP	O
absorption	NN	O
with	IN	O
a	DT	O
SmartSpec	NNP	O
3000	CD	O
spectrophotometer	NN	O
(	(	O
Bio-Rad	NNP	O
)	)	O
.	.	O
H1	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
conditioned-medium	NN	O
on	IN	O
Matrigel	NNP	O
for	IN	O
32	CD	O
passages	NNS	O
,	,	O
the	DT	O
WA15	NNP	O
and	CC	O
WA16	NNP	O
cells	NNS	O
were	VBD	O
cultured	VBN	O
in	IN	O
TeSR1	NNP	O
on	IN	O
human	JJ	O
matrix	NN	O
for	IN	O
9	CD	O
and	CC	O
10	CD	O
passages	NNS	O
respectively	RB	O
.	.	O
Transcripts	NNS	O
were	VBD	O
visualized	VBN	O
on	IN	O
ethidium	NN	O
bromide	NN	O
stained	VBD	O
agarose	JJ	O
gels	NNS	O
.	.	O
For	IN	O
each	DT	O
cell	NN	O
line	NN	O
,	,	O
cytogenetic	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
20	CD	O
metaphase	NN	O
cells	NNS	O
using	VBG	O
G-banding	NNP	O
.	.	O
For	IN	O
long	JJ	O
term	NN	O
cell	NN	O
cultures	NNS	O
(	(	O
H9	NNP	O
,	,	O
21	CD	O
passages	NNS	O
in	IN	O
TeSR1	NNP	O
)	)	O
and	CC	O
newly	RB	O
derived	VBN	O
cell	NN	O
lines	NNS	O
(	(	O
WA15	NNP	O
and	CC	O
WA16	NNP	O
,	,	O
10	CD	O
passages	NNS	O
in	IN	O
culture	NN	O
)	)	O
,	,	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
(	(	O
FISH	NNP	O
)	)	O
was	VBD	O
also	RB	O
performed	VBN	O
on	IN	O
interphase	NN	O
nuclei	NN	O
using	VBG	O
probes	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
TEL	NNP	O
gene	NN	O
on	IN	O
chromosome	NN	O
12	CD	O
and	CC	O
the	DT	O
Her-2/neu	NNP	O
gene	NN	O
on	IN	O
chromosome	NN	O
17	CD	O
.	.	O
Two	CD	O
hundred	JJ	O
cells	NNS	O
were	VBD	O
examined	VBN	O
from	IN	O
each	DT	O
cell	NN	O
line	NN	O
.	.	O
Trisomy	$	O
12	CD	O
and/or	NN	O
17	CD	O
,	,	O
commonly	RB	O
reported	VBN	O
in	IN	O
cultured	JJ	O
human	JJ	O
ES	NNP	O
cells	NNS	O
,	,	O
was	VBD	O
not	RB	O
detected	VBN	O
in	IN	O
long	JJ	O
term	NN	O
cultures	NNS	O
of	IN	O
established	VBN	O
cell	NN	O
lines	NNS	O
or	CC	O
initial	JJ	O
(	(	O
4	CD	O
months	NNS	O
)	)	O
cultures	NNS	O
of	IN	O
newly	RB	O
derived	VBN	O
cell	NN	O
lines	NNS	O
.	.	O
After	IN	O
four	CD	O
months	NNS	O
in	IN	O
culture	NN	O
,	,	O
WA16	NNP	O
was	VBD	O
XXY	NNP	O
(	(	O
Klinefelter	NNP	O
syndrome	NN	O
)	)	O
and	CC	O
WA15	NNP	O
was	VBD	O
karyotypically	RB	O
normal	JJ	O
(	(	O
XY	NNP	O
;	:	O
see	VB	O
FIG	NNP	O
.	.	O
14	CD	O
)	)	O
.	.	O
Klinefelter	NNP	O
syndrome	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
human	JJ	O
chromosomal	JJ	O
abnormality	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
this	DT	O
abnormality	NN	O
may	MD	O
have	VB	O
been	VBN	O
present	JJ	O
in	IN	O
the	DT	O
embryo	NN	O
itself	PRP	O
rather	RB	O
than	IN	O
an	DT	O
artifact	NN	O
introduced	VBN	O
by	IN	O
the	DT	O
process	NN	O
of	IN	O
initiating	VBG	O
the	DT	O
stem	NN	O
cell	NN	O
culture	NN	O
.	.	O
After	IN	O
7	CD	O
months	NNS	O
in	IN	O
culture	NN	O
,	,	O
WA16	NNP	O
maintained	VBD	O
its	PRP$	O
initial	JJ	O
karyotype	NN	O
,	,	O
but	CC	O
WA15	NNP	O
became	VBD	O
trisomic	JJ	O
for	IN	O
chromosome	NN	O
12	CD	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
TeSR1	NNP	O
containing	VBG	O
all	DT	O
five	CD	O
factors	NNS	O
(	(	O
bFGF	NN	O
,	,	O
LiCl	NNP	O
,	,	O
GABA	NNP	O
,	,	O
PA	NNP	O
and	CC	O
TGFβ	NNP	O
)	)	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
support	VB	O
feeder-independent	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	JJ	O
culture	NN	O
as	RB	O
well	RB	O
as	IN	O
or	CC	O
better	JJR	O
than	IN	O
fibroblast-conditioned	JJ	O
medium	NN	O
,	,	O
and	CC	O
remarkably	RB	O
,	,	O
these	DT	O
factors	NNS	O
do	VBP	O
not	RB	O
overlap	VB	O
with	IN	O
the	DT	O
factors	NNS	O
demonstrated	VBD	O
to	TO	O
sustain	VB	O
mouse	NN	O
ES	NNP	O
cells	NNS	O
in	IN	O
defined	JJ	O
conditions	NNS	O
(	(	O
Ying	VBG	B
,	,	I
Q.	NNP	I
L.	NNP	I
et	FW	I
al	NN	I
.	.	I
Cell	NNP	I
115	CD	I
,	,	I
281-292	CD	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
Three	CD	O
of	IN	O
the	DT	O
factors	NNS	O
present	VBP	O
in	IN	O
TeSR1	NNP	O
(	(	O
bFGF	NN	O
,	,	O
TGFβ	NNP	O
and	CC	O
LiCl	NNP	O
)	)	O
are	VBP	O
believed	VBN	O
to	TO	O
stimulate	VB	O
signaling	VBG	O
pathways	NNS	O
previously	RB	O
highlighted	VBN	O
in	IN	O
human	JJ	O
ES	NNP	O
cell	NN	O
culture	NN	O
publications	NNS	O
(	(	O
see	VB	O
Xu	NNP	B
,	,	I
C.	NNP	I
et	CC	I
al	NN	I
.	.	I
Stem	NNP	I
Cells	NNP	I
23	CD	I
,	,	I
315-323	CD	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Amit	NNP	B
,	,	I
M.	NNP	I
et	CC	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Reprod	NNP	I
.	.	I
70	CD	I
,	,	I
837-845	CD	I
(	(	I
2004	CD	I
)	)	I
;	:	O
and	CC	O
Sato	NNP	B
,	,	I
N.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Med	NNP	I
.	.	I
10	CD	I
,	,	I
55-63	CD	I
(	(	I
2004	CD	I
)	)	I
)	)	O
.	.	O
We	PRP	O
initially	RB	O
tested	VBD	O
GABA	NNP	O
because	IN	O
microarray	NN	O
results	NNS	O
indicated	VBD	O
increased	JJ	O
expression	NN	O
of	IN	O
the	DT	O
GABA-A	NNP	O
receptor	NN	O
P-3	NNP	O
subunit	NN	O
by	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
(	(	O
see	VB	O
Sperger	NNP	B
,	,	I
J.	NNP	I
M.	NNP	I
et	FW	I
al	NN	I
.	.	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
100	CD	I
,	,	I
13350-13355	CD	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
GABA	NNP	O
is	VBZ	O
an	DT	O
inhibitory	JJ	O
neurotransmitter	NN	O
of	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
,	,	O
and	CC	O
is	VBZ	O
reported	VBN	O
to	TO	O
stimulate	VB	O
proliferation	NN	O
of	IN	O
both	DT	O
neural	JJ	O
and	CC	O
non-neural	JJ	O
tissues	NNS	O
(	(	O
see	VB	O
Watanabe	NNP	B
,	,	I
M.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
Int	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Cytol	NNP	I
.	.	I
213	CD	I
,	,	I
1-417	CD	I
(	(	I
2002	CD	I
)	)	I
)	)	O
.	.	O
We	PRP	O
tested	VBD	O
pipecolic	JJ	O
acid	RB	O
as	IN	O
it	PRP	O
can	MD	O
enhance	VB	O
GABA-A	NNP	O
receptor	NN	O
responses	NNS	O
(	(	O
see	VB	O
Takahama	NNP	B
,	,	I
K.	NNP	I
et	CC	I
al	NN	I
.	.	I
Neuropharmacology	NNP	I
25	CD	I
,	,	I
339-342	CD	I
(	(	I
1986	CD	I
)	)	I
)	)	O
.	.	O
Unlike	IN	O
previous	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
culture	NN	O
media	NNS	O
that	WDT	O
included	VBD	O
proprietary	JJ	O
,	,	O
poorly	RB	O
defined	VBN	O
serum	JJ	O
components	NNS	O
with	IN	O
undisclosed	JJ	O
formulations	NNS	O
,	,	O
all	DT	O
TeSR1	NNP	O
components	NNS	O
are	VBP	O
disclosed	VBN	O
,	,	O
and	CC	O
thus	RB	O
should	MD	O
serve	VB	O
as	IN	O
a	DT	O
starting	NN	O
point	NN	O
for	IN	O
further	JJ	O
optimization	NN	O
by	IN	O
other	JJ	O
investigators	NNS	O
.	.	O
One	CD	O
area	NN	O
requiring	VBG	O
improvement	NN	O
is	VBZ	O
the	DT	O
matrix	NN	O
,	,	O
as	IN	O
the	DT	O
purified	JJ	O
human	JJ	O
matrix	NN	O
components	NNS	O
are	VBP	O
expensive	JJ	O
and	CC	O
provide	VB	O
a	DT	O
potential	JJ	O
route	NN	O
of	IN	O
contamination	NN	O
by	IN	O
human	JJ	O
pathogens	NNS	O
.	.	O
Human	NNP	O
serum	NN	O
albumin	NN	O
is	VBZ	O
the	DT	O
only	JJ	O
component	NN	O
in	IN	O
the	DT	O
TeSR1	NNP	O
medium	NN	O
itself	PRP	O
that	WDT	O
is	VBZ	O
not	RB	O
fully	RB	O
defined	VBN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
components	NNS	O
that	IN	O
co-purify	NN	O
with	IN	O
it	PRP	O
influence	NN	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
.	.	O
Human	NNP	O
serum	NN	O
albumin	NN	O
is	VBZ	O
routinely	RB	O
used	VBN	O
for	IN	O
embryo	JJ	O
culture	NN	O
during	IN	O
in	IN	O
vitro	JJ	O
fertilization	NN	O
procedures	NNS	O
,	,	O
so	IN	O
its	PRP$	O
inclusion	NN	O
in	IN	O
TeSR1	NNP	O
does	VBZ	O
not	RB	O
qualitatively	RB	O
change	VBP	O
the	DT	O
risk	NN	O
of	IN	O
introducing	VBG	O
pathogens	NNS	O
to	TO	O
the	DT	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
but	CC	O
clearly	RB	O
the	DT	O
replacement	NN	O
of	IN	O
this	DT	O
component	NN	O
by	IN	O
cloned	JJ	O
materials	NNS	O
would	MD	O
be	VB	O
desirable	JJ	O
.	.	O
The	DT	O
new	JJ	O
human	JJ	O
ES	NNP	O
cell	NN	O
line	NN	O
WA15	NNP	O
was	VBD	O
initially	RB	O
normal	JJ	O
,	,	O
but	CC	O
converted	VBD	O
to	TO	O
trisomy	VB	O
12	CD	O
between	IN	O
4	CD	O
and	CC	O
7	CD	O
months	NNS	O
of	IN	O
culture	NN	O
.	.	O
The	DT	O
emergence	NN	O
of	IN	O
this	DT	O
abnormal	JJ	O
karyotype	NN	O
could	MD	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
enzymatic	JJ	O
dissociation	NN	O
used	VBN	O
to	TO	O
passage	VB	O
the	DT	O
cells	NNS	O
.	.	O
Trisomy	$	O
12	CD	O
in	IN	O
human	JJ	O
ES	NNP	O
cells	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
previously	RB	O
(	(	O
see	VB	O
Draper	NNP	B
,	,	I
J.	NNP	I
S.	NNP	I
et	FW	I
al	NN	I
.	.	I
Nat	NNP	I
.	.	I
Biotechnol	NNP	I
.	.	I
22	CD	I
,	,	I
53-54	CD	I
;	:	I
2004	CD	I
)	)	O
,	,	O
and	CC	O
in	IN	O
our	PRP$	O
hands	NNS	O
,	,	O
has	VBZ	O
often	RB	O
been	VBN	O
associated	VBN	O
with	IN	O
clonal	JJ	O
events	NNS	O
.	.	O
Human	NNP	O
pluripotent	NN	O
stem	NN	O
cells	NNS	O
clone	NN	O
at	IN	O
a	DT	O
poor	JJ	O
efficiency	NN	O
(	(	O
1	CD	O
%	NN	O
)	)	O
and	CC	O
enzymatic	JJ	O
methods	NNS	O
of	IN	O
dissociation	NN	O
can	MD	O
result	VB	O
in	IN	O
a	DT	O
significant	JJ	O
number	NN	O
of	IN	O
individualized	JJ	O
cells	NNS	O
.	.	O
There	EX	O
is	VBZ	O
,	,	O
therefore	RB	O
,	,	O
significant	JJ	O
selective	JJ	O
pressure	NN	O
for	IN	O
karyotypic	NN	O
changes	NNS	O
that	WDT	O
increase	VBP	O
cloning	VBG	O
efficiency	NN	O
of	IN	O
the	DT	O
cells	NNS	O
.	.	O
Mechanical	JJ	O
methods	NNS	O
of	IN	O
passaging	VBG	O
the	DT	O
cells	NNS	O
that	WDT	O
result	VBP	O
in	IN	O
uniform	JJ	O
clump	NN	O
size	NN	O
or	CC	O
improved	VBN	O
cloning	JJ	O
efficiencies	NNS	O
could	MD	O
significantly	RB	O
reduce	VB	O
these	DT	O
selective	JJ	O
pressures	NNS	O
.	.	O
Clearly	RB	O
,	,	O
a	DT	O
better	JJR	O
understanding	NN	O
of	IN	O
the	DT	O
rate	NN	O
of	IN	O
genetic	JJ	O
change	NN	O
and	CC	O
the	DT	O
selective	JJ	O
pressures	NNS	O
that	WDT	O
allow	VBP	O
those	DT	O
changes	NNS	O
to	TO	O
dominate	VB	O
a	DT	O
culture	NN	O
will	MD	O
be	VB	O
critical	JJ	O
to	TO	O
any	DT	O
therapeutic	JJ	O
application	NN	O
of	IN	O
human	JJ	O
pluripotent	JJ	O
stem	NN	O
cells	NNS	O
.	.	O
Human	NNP	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
derived	VBN	O
in	IN	O
defined	JJ	O
conditions	NNS	O
would	MD	O
be	VB	O
more	RBR	O
directly	RB	O
applicable	JJ	O
to	TO	O
clinical	JJ	O
use	NN	O
than	IN	O
are	VBP	O
cell	JJ	O
lines	NNS	O
derived	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
animal	NN	O
products	NNS	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
currently	RB	O
approved	VBN	O
for	IN	O
federal	JJ	O
funding	NN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
were	VBD	O
derived	VBN	O
on	IN	O
mouse	NN	O
feeder	NN	O
layers	NNS	O
and	CC	O
were	VBD	O
exposed	VBN	O
to	TO	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
poorly	RB	O
defined	VBN	O
animal	JJ	O
products	NNS	O
.	.	O
Derivation	NN	O
and	CC	O
culture	NN	O
in	IN	O
serum-free	JJ	O
,	,	O
animal	JJ	O
product-free	JJ	O
,	,	O
feeder-independent	JJ	O
conditions	NNS	O
mean	VBP	O
that	IN	O
new	JJ	O
human	JJ	O
pluripotent	NN	O
stem	NN	O
cell	NN	O
lines	NNS	O
could	MD	O
be	VB	O
qualitatively	RB	O
different	JJ	O
from	IN	O
the	DT	O
original	JJ	O
lines	NNS	O
,	,	O
enabling	VBG	O
increased	JJ	O
clinical	JJ	O
uses	NNS	O
.	.	O
The	DT	O
disclosure	NN	O
of	IN	O
every	DT	O
patent	NN	O
,	,	O
patent	NN	O
application	NN	O
,	,	O
and	CC	O
publication	NN	O
cited	VBD	O
herein	NN	O
is	VBZ	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
here	RB	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Although	IN	O
the	DT	O
foregoing	JJ	O
invention	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
in	IN	O
some	DT	O
detail	NN	O
by	IN	O
way	NN	O
of	IN	O
illustration	NN	O
and	CC	O
example	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
clarity	NN	O
of	IN	O
understanding	NN	O
,	,	O
it	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
certain	JJ	O
adaptations	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
a	DT	O
matter	NN	O
of	IN	O
routine	JJ	O
optimization	NN	O
for	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
can	MD	O
be	VB	O
implemented	VBN	O
without	IN	O
departing	VBG	O
from	IN	O
the	DT	O
spirit	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
appended	JJ	O
claims	NNS	O
.	.	O
RELATED	JJ	O
PUBLICATIONS	NNP	O
Claims	NNP	O
(	(	O
18	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
7	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
3	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
2	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
2	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=35351611	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
5	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
2	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
2	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
9	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
2	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
55	CD	O
)	)	O
Citations	NNPS	O
(	(	O
9	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
14	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
21	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
4	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
WISCONSIN	NNP	O
ALUMNI	NNP	O
RESEARCH	NNP	O
FOUNDATION	NNP	O
,	,	O
WISCONSIN	NNP	O
Free	NNP	O
format	VBD	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNORS	NNP	O
:	:	O
THOMSON	NN	O
,	,	O
JAMES	NNP	O
;	:	O
LUDWIG	NNP	O
,	,	O
TENNEILLE	NNP	O
;	:	O
SIGNING	NNP	O
DATES	NNP	O
FROM	NNP	O
20100720	CD	O
TO	NNP	O
20110912	CD	O
;	:	O
REEL/FRAME:026960/0403	NNP	O
Year	NNP	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
